

REVIEW

Open Access

# Review of Journal of Cardiovascular Magnetic Resonance 2011

Dudley J Pennell<sup>1,2\*</sup>, John Paul Carpenter<sup>1,2</sup>, David N Firmin<sup>1,2</sup>, Philip J Kilner<sup>1,2</sup>, Raad H Mohiaddin<sup>1,2</sup> and Sanjay K Prasad<sup>1,2</sup>

## Abstract

There were 83 articles published in the *Journal of Cardiovascular Magnetic Resonance* (JCMR) in 2011, which is an 11% increase in the number of articles since 2010. The quality of the submissions continues to increase. The editors had been delighted with the 2010 JCMR Impact Factor of 4.33, although this fell modestly to 3.72 for 2011. The impact factor undergoes natural variation according to citation rates of papers in the 2 years following publication, and is significantly influenced by highly cited papers such as official reports. However, we remain very pleased with the progress of the journal's impact over the last 5 years. Our acceptance rate is approximately 25%, and has been falling as the number of articles being submitted has been increasing. In accordance with Open-Access publishing, the JCMR articles go on-line as they are accepted with no collating of the articles into sections or special thematic issues. For this reason, the Editors feel it is useful to summarize the papers for the readership into broad areas of interest or theme, which we feel would be useful, so that areas of interest from the previous year can be reviewed in a single article in relation to each other and other recent JCMR articles [1]. The papers are presented in broad themes and set in context with related literature and previously published JCMR papers to guide continuity of thought in the journal. We hope that you find the open-access system increases wider reading and citation of your papers, and that you will continue to send your quality manuscripts to JCMR for publication.

## Cardiac volumes, function and mass

CMR is reasonably mature for assessment of cardiac function, with categorization by age decile, gender and body surface area for normal values for the left ventricle (LV) [2], right ventricle (RV) [3] and left atrium [4]. Although values for special groups are still being defined [5,6], a number of research papers are still being published for assessment of less common parameters of cardiac performance [7-9] as well as analysis software [10,11].

## Effect of lifestyle intervention plus rosiglitazone or placebo therapy on left ventricular mass assessed with cardiovascular magnetic resonance in the metabolic syndrome

Patients with the metabolic syndrome are often found to have left ventricular hypertrophy and raised LV mass [12]. Thiazolidinediones (rosiglitazone, pioglitazone and troglitazone) represent a group of insulin sensitizing agents which lower blood glucose levels by enhancing hepatic

and peripheral glucose uptake as well as increasing free fatty acid uptake and storage in adipose tissue (thereby decreasing free fatty acid uptake in other tissues) [13]. Whether thiazolidinediones have a beneficial or adverse effect on LV mass has previously proved controversial. Roes reported the cardiovascular findings in a randomly chosen subset of patients involved in a much larger double-blind randomised controlled trial [14]. This was a trial looking at lifestyle intervention in combination with either rosiglitazone or placebo and its effect on carotid artery atherosclerosis in the metabolic syndrome. Lifestyle intervention resulted in a reduction of indexed LV mass in the placebo group, indicating reverse remodelling but there was no reduction in the rosiglitazone group and the authors suggest that rosiglitazone therapy may have inhibited this positive reverse remodelling.

**Strong cardiovascular prognostic implication of quantitative left atrial contractile function assessed by cardiac magnetic resonance imaging in patients with chronic hypertension**  
Increased left atrial size is a marker of left ventricular diastolic dysfunction and is a direct result of raised left

\* Correspondence: d.pennell@ic.ac.uk

<sup>1</sup>CMR Unit Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK

<sup>2</sup>National Heart and Lung Institute, Imperial College, Exhibition Road, London SW7 2AZ, UK

ventricular end-diastolic pressure. It is a strong prognostic predictor of outcomes in patients with diastolic dysfunction but less is known about the prognostic significance of atrial contractile function. Over a median follow-up period of 19 months, Kaminski studied 210 patients with chronic hypertension who underwent a clinically indicated CMR scan for assessment of left ventricular function, myocardial ischemia or viability [15]. Left atrial contractile function was calculated from indexed biplane area-length measurements. The active component of atrial contractile function showed strong independent associations with major adverse cardiac events (MACE) ( $p < 0.0004$ ), all-cause mortality ( $p < 0.0004$ ), and non-fatal events ( $p < 0.0004$ ) even after adjusting for age, gender, left atrial volume, and LV ejection fraction. This study adds strength to the growing literature on the prognostic value of CMR-derived cardiovascular parameters.

#### **Comparison of long and short axis quantification of left ventricular volume parameters by cardiovascular magnetic resonance, an ex-vivo validation**

It is without doubt that one of the major advantages of CMR over other imaging techniques is the robust measurement of myocardial volumes and mass. High inter-study and interobserver reproducibility makes the technique ideally suited for longitudinal follow-up and can dramatically reduce sample size required for clinical trials [16]. Childs reported a comparison of short-axis derived ventricular volumes versus a novel technique using six radial long-axis steady state free precession (SSFP) cine sequences in explanted canine hearts and in 46 patients referred for CMR assessment [17]. Both short axis and long axis techniques were highly accurate but the rotational long axis approach proved more reproducible and time-efficient (with a 27% shorter evaluation time for experienced operators). A rotational long axis approach may therefore be a viable alternative for the clinical assessment of cardiac volumes, function and mass but would require a redesign of most of the current commercially available CMR analysis packages.

#### **Regional myocardial function after intracoronary bone marrow cell injection in reperfused anterior wall infarction – a cardiovascular magnetic resonance tagging study**

This paper was a report of the CMR tagging substudy of the Autologous Stem Cell Transplantation in Acute Myocardial Infarction trial (ASTAMI), exploring the regenerative effects of intracoronary delivery of autologous mononuclear bone marrow stem cells [18]. Grid tagging using a FLASH gradient echo sequence was performed at 2-3 weeks and at 6 months after successful revascularisation with primary percutaneous intervention in 15 patients and 13 controls presenting with anterior

ST-segment elevation myocardial infarction. The authors found an improvement in global and infarct zone strain in the control group which was greater than that observed in those who had received intracoronary stem cells. Conversely, LV mass decreased more in the control group than the stem cell group. Although the finding that this type of stem cell therapy does not strengthen regional or global myocardial function might seem somewhat disappointing at first glance, investigators in this field are focused on working out the correct stem cells to give and the optimal route of delivery. CMR will be at the forefront of that discovery.

#### **The relative atrial volume ratio and late gadolinium enhancement provide additive information to differentiate constrictive pericarditis from restrictive cardiomyopathy**

The differentiation of restrictive cardiomyopathy from pericardial constriction can be challenging as both conditions may have similar imaging features but require a very different management strategy. Patients with surgically documented pericardial constriction ( $n=23$ ), restrictive cardiomyopathy ( $n=22$ ) and normal subjects ( $n=25$ ) were included in this study [19]. Cheng et al. compared left and right atrial volumes using a relative atrial volume ratio (RAR) defined as the LA volume divided by the RA volume. Using a cut-off value of 1.32 for the RAR, the sensitivity for the detection of constriction was 82.6%, with a specificity of 86.4%. Septal bounce was identified in 95.7% of constriction patients but in none of the patients with restriction or the normal subjects. Late gadolinium enhancement was present in 31.8% of those with restrictive cardiomyopathy but absent in all constriction patients and normals. Non-invasive techniques such as CMR often rely on indirect findings and the potential development of robust diagnostic criteria with the ability to distinguish constriction from restriction is very welcome for the practicing clinician.

#### **Cardiovascular magnetic resonance myocardial feature tracking detects quantitative wall motion during dobutamine stress**

CMR myocardial feature tracking is a new technique which attempts to track myocardial motion at voxel level from standard steady-state-free-precession cine acquisitions. The technique generates values for circumferential and radial strain, and is not currently validated or in clinical use. Schuster et al performed feature tracking on 10 normals at 1.5 T using the 4 chamber view [20]. Studies were performed at rest and during dobutamine stress. Strain was measurable in all patients and at rest and stress. Values increased significantly with dobutamine in parallel with the increase in ejection fraction.

Observer variability was best for LV circumferential strain. The authors conclude that feature tracking may develop into a useful clinical tool with further development and validation.

#### **Right ventricular dysfunction is a predictor of non-response and clinical outcome following cardiac resynchronization therapy**

Cardiac resynchronization therapy (CRT) is of proven benefit in advanced heart failure, but an important subset do not respond. CMR has been increasingly used to study patients requiring CRT [21]. Alpendurada et al. studied the incremental significance of right ventricular function in predicting benefit from CRT in 60 patients [22]. In a multivariate model, only RV ejection fraction and myocardial scar burden were significant predictors of response to CRT. Patients with RV EF < 30% had a particularly poor response rate (18.2%). The authors suggest that RV function should be measured in patients being evaluated for CRT.

#### **Flow evaluation and valve disease**

The capability of CMR to measure cardiovascular flow contributes greatly to the versatility of CMR in clinical practice, and development of baseline flow corrections [23], and automated analysis software [24] continues. This has greatest application in valve disease [25-27] but it is also often used in disease of the aorta [28,29], lungs, coronaries and in congenital heart disease.

#### **Cardiovascular magnetic resonance for the assessment of patients undergoing transcatheter aortic valve implantation: a pilot study**

Correlation and agreement between transthoracic echocardiography (TTE) and CMR in the assessment of aortic root dimension and LV morphology and function were studied in 49 patients undergoing transcatheter aortic valve implantation (TAVI) [30]. There was a good correlation between TTE and CMR in terms of annulus size ( $R^2 = 0.48$ ,  $p < 0.001$ ), left ventricular outflow tract (LVOT) diameter ( $R^2 = 0.62$ ,  $p < 0.001$ ) and left ventricular ejection fraction (LVEF) ( $R^2 = 0.47$ ,  $p < 0.001$ ) and a moderate correlation in terms of aortic valve area (AVA) ( $R^2 = 0.24$ ,  $p < 0.001$ ). CMR generally tended to report larger values than TTE for all measurements. Bland-Altman analysis indicated that the 95% limits of agreement between TTE and CMR ranged from -5.6 mm to +1.0 mm for annulus size, from -0.45 mm to +0.25 mm for LVOT, from -0.45 mm<sup>2</sup> to +0.25 mm<sup>2</sup> for AVA and from -29.2% to 13.2% for LVEF. CMR represents a viable complementary imaging method to TTE in elderly patients being considered for TAVI.

#### **Pseudoaneurysm of the left ventricle following apical approach TAVI**

This is an interesting case report of a pseudoaneurysm of the left ventricle following trans-apical TAVI approach in an elderly lady with severe aortic stenosis [31]. A 23 mm Edwards Scientific Sapien XT valve prosthesis (a bovine tissue valve inserted on a cobalt chromium frame) was implanted with immediate transoesophageal echocardiography and fluoroscopic imaging demonstrated excellent seating of the valve, subsequently confirmed angiographically. Two days later the patient developed isolated electrocardiographic evidence of pericarditis with minimal associated chest pain. Transthoracic echocardiography demonstrated a well seated aortic prosthesis and a 0.8 cm pericardial effusion with no tamponade. The effusion was not drained and her electrocardiographic changes settled over the next few days. Three months later, transthoracic echocardiography showed a discrete pseudoaneurysm with late gadolinium myocardial enhancement. She was managed conservatively with regular surveillance.

#### **Contrast-enhanced CMR in patients after percutaneous closure of the left atrial appendage: A pilot study**

There are currently a number of commercially available devices for left atrial appendage (LAA) closure to prevent the formation of thrombus and risk of stroke in atrial fibrillation. However, imperfect device placement or suboptimal 'fit' causing a residual 'leak' into the LAA has the potential to allow thrombus to form. This would mandate that the patient remains on long-term anticoagulation medication, thereby negating the potential benefit from device implantation. Mohrs' pilot study of 7 patients with three different device occluders (Watchman, PLAATO and ACP) assessed the feasibility of using CMR to detect residual leaks around the devices [32]. First-pass perfusion using SSFP was followed by a 3D Turbo-FLASH sequence. The authors found a very high percentage with residual leaks (57%) but noted that the study only included patients in whom problems of device malposition or residual leaks were suspected. There are still questions to be answered (including whether CMR is able to detect small thrombi on the device surface) but this very interesting approach is likely to inform future device design and procedural quality control.

#### **Sequence optimization to reduce velocity offsets in cardiovascular magnetic resonance volume flow quantification - A multi-vendor study**

This manuscript describes a follow-up study to the multi-vendor, multi-centre study by Gatehouse in which they measured offsets in phase contrast velocity mapping studies [33]. In this paper, the effects on velocity

offsets of changes to the exam protocol parameters were examined, with the goal of finding a method to minimise offsets at the acquisition stage without the need of post-processing correction schemes [34]. Although important, the conclusion was perhaps overly negative in stating that with current systems there was no generic protocol which resulted in acceptable flow offset values.

### **Congenital and pediatric heart disease**

Congenital heart disease remains a major indication for CMR, and makes particular contribution in the assessment of the major vessels [35], shunt assessment [36], in complex anatomy, and increasingly in children and neonates [37]. A wide range of clinical scenarios in congenital heart disease were covered in JCMR in 2011.

#### **Cardiovascular magnetic resonance tagging of the right ventricular free wall for the assessment of long axis myocardial function in congenital heart disease**

Quantification of right ventricular myocardial function and any changes of it over time are important issues in congenital heart disease. Volumetric calculation of right ventricular (RV) ejection fraction is time consuming to acquire and analyse, and inter-study reproducibility is suboptimal. In this study, a linear tag orientated perpendicular to the basal free wall of the RV was used to measure long axis systolic displacement [38]. The method was quick to acquire and analyse, reproducible and showed more significant differences between the clinical groups studied than did RV ejection fraction. This suggests it has potential as an additional method, particularly for longitudinal comparisons.

#### **3D Echo systematically underestimates right ventricular volumes compared to cardiovascular magnetic resonance in adult congenital heart disease patients with moderate or severe RV dilatation**

Three dimensional echo is a relatively new technique which promises to offer a rapid alternative to CMR for the examination of the right heart. In this study, comparison of 3D echo with CMR measurements of RV volumes and function was undertaken in patients with varying degrees of RV dysfunction resulting from congenital heart disease [39]. The echo technique was found to underestimate RV volumes significantly, especially in patients with more severe dilatation and dysfunction. This led the authors to conclude that 3D echo, as implemented, was not ready for routine clinical use for the assessment of more than mild dilatation of the RV.

#### **Assessment of pulmonary veins after atrio-pericardial anastomosis by cardiovascular magnetic resonance**

Surgical anastomoses of pulmonary veins are prone to re-stenosis, especially if attempted in the small, delicate

veins of infants. For this reason, atrio-pericardial anastomosis uses a pericardial pouch to create a large communication between the left atrium and the pulmonary veins. It avoids direct suturing of the pulmonary veins during the repair of various congenital malformations. This study reviewed CMR assessments of this approach, performed in 31 of the 103 patients undergoing the procedure [40]. Findings were compared with those by echocardiography, concluding that CMR gave a more thorough assessment. Even after the atrio-pericardial anastomotic technique, stenosis of the pulmonary veins remained a common complication, being identified in 12 of the 31 CMR studies performed.

#### **The role of cardiovascular magnetic resonance in candidates for fontan operation: proposal of a new algorithm**

Fontan surgery, performed for children with only one effective ventricle, involves reconnection of the systemic venous returns to the pulmonary arteries so that the one effective pump delivers flow to the systemic and then the pulmonary vasculature in series. The procedure requires careful pre-operative planning. After reviewing the investigations performed and their findings in 44 patients undergoing Fontan surgery, the authors of this paper propose a pre-procedure investigative-diagnostic algorithm [41]. They found that a combination of trans-thoracic echocardiographic and CMR investigations can be used to triage patients, some of whom can then proceed to surgery without the need for cardiac catheterisation.

#### **The role of cardiovascular magnetic resonance in pediatric congenital heart disease**

CMR is rapidly coming to be regarded as an indispensable imaging and investigative modality in paediatric cardiology. However, imaging small children with congenital heart disease is challenging. This paper provides an authoritative and clearly written review of the technical adjustments, imaging protocols and applications of CMR in the paediatric population [42].

#### **Delayed onset of tricuspid valve flow in repaired tetralogy of Fallot: an additional mechanism of diastolic dysfunction and interventricular dyssynchrony**

Those who routinely image patients with dilated and/or pressure loaded RVs are likely to have noticed signs of prolonged systole of the RV relative to that of the LV. This study used phase contrast velocity mapping to record the time course of tricuspid and mitral flow in 31 children with repaired tetralogy of Fallot [43]. The authors found delayed onset of tricuspid flow to be common in this group and associated with reduced RV ejection fraction. This manifestation of interventricular



dysynchrony may be one of several possible mechanisms of ventricular diastolic dysfunction.

**Quantitative cardiovascular magnetic resonance in pregnant women: cross-sectional analysis of physiological parameters throughout pregnancy and the impact of the supine position**  
CMR study of an expectant mother's haemodynamics is feasible and acceptable during mid to late pregnancy. It may be more comfortable in a left lateral than the supine position. This study of healthy pregnant women, 6 in mid pregnancy and 8 late in pregnancy, compared haemodynamic parameters and the effects of position on them [44]. It concluded that, from as early as 20 weeks, the left lateral position appears to be preferable. This was based on the greater stroke volumes and cardiac outputs measured in this position than supine, which presumably tends to put pressure on systemic veins from the lower body.

**Comparison between cardiovascular magnetic resonance and transthoracic Doppler echocardiography for the estimation of effective orifice area in aortic stenosis**

This study compared CMR and echocardiographic approaches to assessments of aortic stenosis (AS) using the continuity approach that incorporates calculations of volume flow at left ventricular outflow tract (LVOT) level, and the post stenotic jet velocity time integral [45]. CMR showed the LVOT cross-section to be ovoid, not circular, and that Echo, which typically recorded the smaller ovoid diameter, tended to underestimate this area. On the contrary, CMR tended to underestimate jet velocities relative to echo. These presumed errors tended to cancel out, resulting in little mean difference between the echo and CMR calculations of effective orifice area. However, CMR was associated with less intra- and inter- observer variability of measurement. Some readers may prefer to measure stenotic orifice area directly by planimetry from one of a stack of appropriately acquired CMR cines, aligned to transect the jet near its origin. This relatively straightforward approach was not investigated in the study reported.

**Pulmonary flow profile and distensibility following acute pulmonary embolism**

This study used phase contrast CMR to record pulmonary artery flow in groups of patients with and without pulmonary embolus detected by computed tomography (CT) about 6 months previously [46]. Both groups had been investigated for suspicion of PE. The sample sizes were relatively small and the CMR measures followed the initial months of therapy. Although RV functional differences had been documented by initial CT, no significant differences were found in the amounts or the temporal profiles of pulmonary flow by the CMR studies. It remains unclear whether the lack of difference

depended on the time interval and the therapy given. Only one of the patients had evidence of pulmonary hypertension at the time of CMR, which recorded the characteristic notch or depression in mid systolic flow and a reduction of peak velocity that are expected with elevated pulmonary vascular resistance.

**Repaired tetralogy of Fallot: the roles of cardiovascular magnetic resonance in evaluating pathophysiology and for pulmonary valve replacement decision support**

Tetralogy of Fallot is one of the commonest and most important congenital heart conditions whose management after surgical repair calls for serial follow up by CMR. The author gives a comprehensive and thoughtful review of the methods and interpretation of CMR studies in relation to the pathophysiology of condition [47]. This review is recommended for reference and for explanations of methods and measurements that are currently considered to contribute most to clinical decision making.

**Comprehensive 4D velocity mapping of the heart and great vessels by cardiovascular magnetic resonance**

Four dimensional (4D) phase contrast velocity mapping is a relatively novel and impressive CMR technique. It entails the acquisition of all 3 directional components of velocity for voxels distributed in all 3 dimensions of space, triggered over many heart cycles to represent multiple phases of the cardiac cycle. This paper reviews and illustrates the methods used for the acquisition, visualization, and quantification of 4D velocity datasets, which typically takes ten or more minutes [48]. Although more rapid and user-friendly strategies for acquisition and analysis may be needed before 4D velocity acquisitions come to be adopted in routine clinical CMR, their capacity to measure multidirectional flows throughout a study volume has contributed novel insights into cardiovascular fluid dynamics in health and disease.

**Cardiovascular magnetic resonance findings in repaired anomalous left coronary artery to pulmonary artery connection (ALCAPA)**

Secinaro reported the use of CMR in a series of 6 patients at Great Ormond Street Hospital, London with clinical suspicion of ischemia following surgical repair for anomalous left coronary artery to pulmonary artery connection (ALCAPA) [49]. The mean age was  $15.3 \pm 4.2$  years and half were female. Their protocol included volumes and function, late gadolinium, adenosine stress perfusion and 3D whole heart acquisition to assess coronary artery origins. In this cohort, basal anterolateral subendocardial myocardial fibrosis was a characteristic finding. Stress perfusion identified reversible ischemia in 3 patients which was indicative of left coronary artery occlusion, confirmed at coronary angiography in all 3.

This study confirms CMR as a reasonable non-invasive first-line investigation for the assessment of such patients.

### **Iron overload cardiomyopathy**

Since the first data on myocardial T2\* CMR published in 2001 [50], there has been substantial and rapid progress in the use of this technique for patient benefit, with direct calibration to myocardial iron concentration [51], the association of myocardial T2\* < 10 ms with adverse cardiac outcomes [52], and a reduction in cardiac mortality [53]. These 5 JCMR papers in 2011 continue to define the role of T2\* in multiply transfused patients.

### **On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure**

This paper analyzes the importance of increases in ejection fraction during treatment with iron chelators for myocardial siderosis on the future likelihood of developing heart failure, which is the most dangerous complication of multiple transfusions as the historical mortality is high once heart failure develops [54]. The premise behind the analysis is that both the absolute level and the trajectory of ejection fraction are useful markers of heart failure risk. A UK database was analyzed for patients with at least two CMR scans (with T2\* and ejection fraction) with follow-up for development of heart failure. A total of 315 patients were included in the analysis, and patients were stratified into normal or reduced baseline ejection fraction. Statistical modelling showed that an improvement in ejection fraction was associated with a significantly lower risk of developing heart failure irrespective of baseline ejection fraction. However, the absolute risk of developing heart failure was greater in patients with lower ejection fraction. Using data on ejection fraction change from randomized controlled trials, the authors showed that the ejection fraction changes seen with oral deferiprone were associated with a 25.5% to 46.4% reduction in risk of developing heart failure. This is important because other iron chelators are not associated with such increases in ejection fraction despite improving myocardial T2\*. The authors suggest that this difference between the iron chelators might be explained by the preferential relief by deferiprone of iron-related mitochondrial dysfunction.

### **Value of black blood T2\* cardiovascular magnetic resonance**

The CMR sequence used to measure myocardial T2\* has gone incremental improvement since the first use of a non-breathhold sequence which was influenced by tissue T1 in 2001. A single breathhold multi-echo sequence was introduced in 2003 and was shown to be reliable and reproducible [55]. However, these white blood sequences were subject to artefactual signal from the white blood

pool smeared in the phase encode direction. This was problematic in hearts with heavy iron loading and at the longer echo times. He et al introduced the dark blood T2\* sequence in 2007 [56] and in this paper Smith compares the white and black blood sequences [57]. The authors show that the black blood sequence had significantly improved intra-observer, inter-observer, and inter-study reproducibility. In addition, the black blood sequence has fewer imaging artefacts. Therefore, this sequence is recommended for clinical use.

### **Low prevalence of fibrosis in thalassemia major assessed by late gadolinium enhancement cardiovascular magnetic resonance**

Post-mortem reports in the 1960s and 1970s showed that patients dying of myocardial siderosis had severe replacement myocardial fibrosis. If this were the case today, it would be expected that heart failure related to myocardial siderosis would be irreversible. However, recent studies with aggressive intravenous iron chelation [58] have shown that it is possible to survive siderotic heart failure and regain normal cardiac function [59]. Kirk examined 45 thalassemia major patient using late gadolinium enhancement and found only one patient with enhancement [60]. No patient with a history of heart failure or low ejection fraction had LGE. The authors conclude that replacement myocardial fibrosis is unusual in the modern era, possibly due to the influence of increased use of transfusions, lower infection rates, or increased use of iron chelation treatments.

### **Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload**

Considerable attention has been paid to the effect of iron overload on the left ventricle, but little to its effects on the right ventricle. Recent work has shown normal right ventricular function in thalassemia [61], and its decline with myocardial iron loading [62]. This paper by Smith shows the effect of the iron chelators deferiprone and deferoxamine on right ventricular function [63]. Deferiprone increased right ventricular ejection fraction and reduced the end-systolic volume. Deferoxamine however, had no effect on right ventricular volumes or ejection fraction. The effects of the oral drug deferiprone with significantly superior to those of the injectable deferoxamine, and may contribute to the improved mortality seen with deferiprone.

### **Iron overload in polytransfused patients without heart failure is associated with subclinical alterations of systolic left ventricular function using cardiovascular magnetic resonance tagging**

Although myocardial T2\* has been successfully introduced into clinical practice, it is not as available as it needs to be in lower income countries where thalassemia

is prevalent. Seldrum examines CMR tagging as a possible alternative measure to detect myocardial iron [64]. In 10 patients with myocardial  $T2^* < 10$  ms, the authors showed that subclinical alterations in cardiac function of which left ventricular twist was the earliest to show abnormality and correlated best with  $T2^*$ . Although this is of interest, in clinical practice, myocardial  $T2^*$  is more specific for siderosis and tagging is less available and more complicated to analyse than myocardial  $T2^*$ .

### **Cardiomyopathy**

CMR of patients with cardiomyopathy has become a leading referral over the last 5 years and there has been considerable interaction with cardiovascular geneticists as CMR offers high fidelity phenotyping [65], that augments genetic discovery [66]. CMR physicians have also started to work closely with electrophysiology colleagues to assess arrhythmic and sudden death risks [67]. Conditions related to cardiomyopathy [68,69], and rare forms of cardiomyopathy [70,71], are being studied and common themes of myocardial fibrosis development, pattern of deposition, strain patterns [72] and association with outcomes are being established [73]. CMR techniques continue to develop [74], most recently the technique of equilibrium T1 mapping after gadolinium to assess the interstitial compartment has become popular [75], although this is not straightforward and clinical application is not yet established. T2 mapping is also being investigated for its utility [76], and may be useful in combination with late gadolinium enhancement in conditions such as myocarditis [77].

### **Hypertrophic cardiomyopathy and ultra-endurance running - two incompatible entities?**

Hypertrophic cardiomyopathy (HCM) is often described as associated with a reduced exercise capacity, perhaps best demonstrated by a reduced peak  $VO_2$ . It is also often considered that in patients with unexplained LV hypertrophy, a suboptimal  $VO_2$  is a hallmark of HCM rather than hypertensive disease. This case study reports an asymptomatic male athlete with 25 years of ultra-endurance competition, with genetically confirmed HCM phenotypically manifesting with LVH, a small LV cavity together with repolarisation abnormalities suggestive of HCM [78]. The authors speculate that despite documented asymmetric hypertrophy and focal myocardial fibrosis in the basal anteroseptal and inferoseptal walls, it is suspected that the athlete is able to run ultra-marathons due to a compliant LV with normal diastolic and systolic parameters, which is able to augment stroke volume.

### **Increased left ventricular torsion in hypertrophic cardiomyopathy mutation carriers with normal wall thickness**

In concert with major developments in genetic techniques an important group of patients are those that are

gene positive and phenotypically negative, particularly in HCM. What is controversial is determining early markers of disease before the phenotype has manifested. In this study of 17 HCM mutation carriers, and normal wall thickness, using tissue tagging it was observed that there was increased LV torsion as well as endocardial circumferential strain and torsion-to-endocardial-circumferential-shortening ratio, which reflects the transmural distribution in contractile function [79]. Further work is required to determine if this may offer a potential therapeutic target.

### **Myocardial extravascular extracellular volume fraction measurement by gadolinium cardiovascular magnetic resonance in humans: slow infusion versus bolus**

Detection of interstitial fibrosis is one of the most exciting fields in CMR at present. There is still much controversy over sequence types, and in particular whether slow infusion carries significant advantage over the more practical bolus option. In this study of 10 volunteers, serial  $V_e$  measures were compared across the 2 methods [80]. Importantly, serial measures of  $V_e$  did not differ significantly between the constant infusion and bolus methods. There is strong correlation of readings to age. The findings of this work support development of T1 mapping for extracellular volume fraction (ECV) using the more pragmatic bolus approach that is also likely to simplify clinical application.

### **Myocardial T1 and extracellular volume fraction mapping at 3 Tesla**

Late gadolinium enhancement (LGE) has been the standard of reference for detecting focal myocardial fibrosis in clinical however, it relies on the differences in signal intensity between scarred and adjacent normal myocardium to generate image contrast. T1 mapping, is a promising quantitative method for detecting diffuse myocardial fibrosis. It has potential to provide significant insights into myocardial function. In this study, after validation of MOLLI sequences at 3 T in Phantoms, the authors present values for myocardial and blood T1 pre and post gadolinium contrast at 3 T [81]. At 3 T, post-gadolinium ECV is stable between 8.5 and 23.5 minutes after gadolinium injection.

### **The clinical impact of late gadolinium enhancement in Takotsubo cardiomyopathy: serial analysis of cardiovascular magnetic resonance images**

Takotsubo cardiomyopathy, also known as a stress-induced cardiomyopathy, refers to the transient LV apical ballooning observed after some form of stress that usually resolves. Part of the diagnosis assumes unobstructed coronaries. There is controversy over the presence of fibrosis. In this study, they observe that in 8

patients scanned serially in the sub-acute and late phase (1.5 and 6 months later), the presence of LGE in the subacute phase was associated with greater disease severity and more prolonged recovery [82]. These findings, if supported by larger studies would help stratify what is increasingly recognised as a heterogeneous cohort of patients and presentations.

#### **Cardiovascular magnetic resonance in wet beriberi**

Wet Beriberi is one of four clinical syndromes associated with Thiamine (Vitamin B1) Deficiency. Wet beriberi has varying degrees of cardiovascular involvement. In its most fulminant form, it is characterized by hypotension, tachycardia and lactic acidosis. If untreated, patients die within hours from circulatory collapse and pulmonary edema. This condition often goes unrecognized since it is easily confused with other illnesses. This is the first report demonstrating the CMR finding of myocardial edema associated with wet beriberi and uses a T2 mapping technique to gauge quantitative assessment [83]. Whilst an unusual case, it has relevance at a global level to those who encounter such patients and shows the application of T2 mapping in myocarditic settings.

#### **Cardiovascular magnetic resonance of cardiomyopathy in limb girdle muscular dystrophy 2B and 2I**

Limb-girdle muscular dystrophy (LGMD) comprises a group of genetically-heterogeneous disorders that present with variable skeletal and cardiac muscle involvement. LGMD produces progressive weakness of proximal shoulder-girdle or pelvic muscles with a wide range of phenotypic expression, severity, and age of disease onset. What is less clear is the extent and degree of cardiac involvement. In this study, consecutive patients with genetically-proven LGMD types 2I (n = 7) and 2B (n = 9) and 8 control subjects were enrolled [84]. All subjects underwent CMR with cine imaging for left ventricular volume and ejection fraction measurement, vector velocity analysis of cine data to calculate myocardial strain, and late post-gadolinium enhancement imaging to assess for myocardial fibrosis. The majority of patients with LGMD of 2 subtypes - 2B, and 2I - in this cohort showed normal LV size, global systolic function and peak systolic circumferential strain. However, there was evidence of subclinical myocardial fibrosis in 57% of subjects with LGMD2I and 33% of subjects with LGMD2B. This abnormality was accompanied by diastolic dysfunction in a number of patients. Overall, the prevalence of advanced cardiomyopathy in patients with LGMD2I and LGMD2B appears to be limited in this cohort of patients, but subclinical fibrosis and diastolic dysfunction do occur and may warrant use of cardioprotective medical therapies.

#### **Late gadolinium enhanced cardiovascular magnetic resonance of lamin A/C gene mutation related dilated cardiomyopathy**

The lamin A/C gene (LMNA) is so far the most significant disease gene identified clinically for dilated cardiomyopathy (DCM). It has been estimated that LMNA mutations cause up to 10% of familial DCM. The penetrance of the LMNA mutations causing cardiomyopathy is nearly complete. It is associated with an increased risk of sudden death and heart-failure. The main aim of this study was to characterise myocardial fibrosis, regional wall motion abnormalities, ventricular dilatation, longitudinal LV systolic function and global function with LGE CMR in asymptomatic or mildly symptomatic carriers of LMNA mutations causing DCM [85]. They also looked at the possible association between the localisation of myocardial fibrosis and the conduction abnormalities documented with electrocardiography. This is a relatively small study of 17 patients but what was interesting was that 88% had demonstrable myocardial fibrosis. Where present, there was an association with conduction abnormalities. A high proportion also had mild LV dilatation, impairment in function or longitudinal systolic function. As our genetic capabilities expand, the close link between genotype and phenotype is likely to yield interesting and important findings. It will also be interesting to see the phenotypic manifestations and subsequent clinical implications of the newly identified titin mutation that has been identified to account for about 30% of cases of familial DCM.

#### **Cardiac resynchronization therapy guided by late gadolinium-enhancement cardiovascular magnetic resonance**

Cardiac resynchronization therapy has become an important mainstay in the management of patients with heart-failure. Unfortunately, about 30% of patients do not seem to show a clinical response. As a relatively expensive form of treatment, there is a need for better stratification of Patient selection and also to deploy better methods of optimizing lead placement at the time of implantation. In this study, the authors assessed whether the use of late gadolinium enhancement CMR scan to guide deployment of the LV lead in a non-scarred segment of the LV free wall leads to a better long-term outcome from CRT than using a conventional implantation approach [86]. This is a large study of 559 patients with heart-failure due to both an ischaemic related and non-ischaemic basis. Implantations were either guided (+CMR) or not guided (-CMR) by LGE-CMR prior to implantation. Fluoroscopy and LGE-CMR were used to localize the LV lead tip and myocardial scarring retrospectively. Clinical events were assessed in three groups: +CMR and pacing scar (+CMR + S); CMR and not pacing scar (+CMR-S), and; LV pacing not guided



by CMR (-CMR). With longterm follow-up, over a maximum period of 9 years, the + CMR + S group had the highest risk of death from pump-failure and sudden death, compared to the other cohorts, and lowest in the + CMR-S group. These findings highlight the potential for CMR to guide CRT lead deployment but also that pacing scarred tissue is associated with a much worse outcome – presumably due to provoking re-entrant arrhythmias.

#### **Cardiovascular magnetic resonance in cardiac sarcoidosis with MR conditional pacemaker in situ**

One of the main challenges confronting CMR is the burgeoning number of patients with conventional pacemakers/devices implanted. Whilst under certain restricted conditions, some sites are proceeding with CMR in these patients, and where there is an overwhelming benefit to risk balance, most sites remain conservative in their approach. For this reason, there has been great interest in MR-conditional devices. In this interesting case report, Quarta and colleagues describe how the management of a Patient with sarcoid and such a device, was facilitated by being able to perform CMR on the heart and secondly the impact of their findings [87]. Image quality was excellent and supports the case that there should be growing use of MR-conditional devices to ensure we do not preclude patients from deriving the benefits of CMR.

#### **Mild hypothermia delays the development of stone heart from untreated sustained ventricular fibrillation - a cardiovascular magnetic resonance study**

Manoeuvres to improve outcomes following a ventricular fibrillation (VF) arrest are likely to improve the current suboptimal outcomes. In this study of 14 swine randomised to normothermia or hypothermia, the latter reduced the early LV dilatation typically seen and importantly, delayed the onset of stone heart thereby extending a known, morphologic limit of resuscitability [88]. These findings have important implications to algorithms for managing a VF arrest.

#### **T2-weighted cardiovascular magnetic resonance in acute cardiac disease**

This excellent review assesses the impact of T2-weighted imaging in the assessment of acute cardiac disease [89]. Applications include the assessment of myocardial salvage as well as detection of acute myocarditis. Key strengths lie in its combination with late enhancement imaging. Whilst much focus has been on its diagnostic value, important newer areas are quantifying the area at risk and providing a quantitative means of assessing disease burden to determine therapeutic efficacy and gauge risk. Future work needs to focus on improving sensitivity, better quantification, timescale of changes, and what

the true incremental value is for example in ACS in large well planned outcome studies.

#### **Effects of steroids and angiotensin converting enzyme inhibition on circumferential strain in boys with Duchenne muscular dystrophy: a cross-sectional and longitudinal study utilizing cardiovascular magnetic resonance**

Whilst it is well recognised that Duchenne muscular dystrophy (DMD) carries an increased risk of cardiac morbidity, treatment of this cohort of patients suffers from a lack of systematic prospective clinical trials. In this study, the authors identified patients for inclusion in one of two treatment groups [90]. Group A was only treated with corticosteroids (either deflazacort or prednisone). Group B was being treated with corticosteroids plus ACEi (lisinopril or enalapril) or ARB (losartan). All patients in Group B had been treated with ACEi/ARB for a minimum of 12 months prior to CMR, and all patients in both groups had been treated with corticosteroids for at least 12 months prior to CMR. Initiation of corticosteroids and ACEi/ARB was determined exclusively by treating physician preference and were not based on CMR results. DMD boys not treated with corticosteroids or treated with beta blockers were excluded. Limitations include the lack of randomisation, physician preference in treatment, retrospective nature and lack of control. Notwithstanding, in 171 patients – a large cohort, there was no clear difference in slowing the decline in cardiac function. It highlights the need for ongoing work to look at more novel or targeted treatment strategies.

#### **Prevalence and distribution of regional scar in dysfunctional myocardial segments in Duchenne muscular dystrophy**

Duchenne muscular dystrophy (DMD), is the most common of the muscular dystrophies. It has an incidence of 1 in 3,500 males. It is an X-linked recessive disorder resulting from a disabling mutation of the gene encoding dystrophin, a sarcolemmal protein found in skeletal and cardiac muscles. There is progressive skeletal muscle weakness with loss of ambulatory ability in the teenage years. Death is usually due to cardiac or respiratory failure, and distinctive pathologic findings have been noted. As noted by the authors, with improvements in overall management and respiratory treatment, there has been increasing focus on the prevention and treatment of cardiac disease in this condition. In this study, strain using myocardial tagging and fibrosis patterns were determined in a cohort of 16 patients with DMD [91]. There was also correlation with echo assessed segmental strain. Scar tissue was found to most common in the inferio, inferolateral and anterolateral walls, although seen in other regions as well. The relationship between scar and

circumferential strain is however a little more complex with high negative but lower positive predictive for Ecc in the determining segments with scar.

#### **Presence of mechanical dyssynchrony in Duchenne muscular dystrophy**

As noted above, DMD carries a high morbidity and mortality rate with cardiac dysfunction an important cause. In this large study of 236 Patients with DMD, dyssynchrony was assessed based on timing of CMR derived circumferential strain (ecc) [92]. The calculated indices included cross-correlation delay (XCD), uniformity of strain (US), regional vector of variance (RVV), time to maximum strain (TTMS) and standard deviation (SD) of TTMS. Abnormal XCD value was defined as  $> \text{normal} + 2\text{SD}$ . As noted by the authors, there was overall low prevalence of circumferential dyssynchrony in the entire DMD population; it increased to 17.1% for patients with abnormal EF and to 31.2% in the most advanced stage (abnormal EF with fibrosis). All but one DMD patient with mechanical dyssynchrony exhibited normal QRS duration suggesting absence of electrical dyssynchrony. The calculated US and RVV values ( $0.91 \pm 0.09$ ,  $1.34 \pm 0.48$ ) indicate disperse rather than clustered dyssynchrony. Patients also had a high prevalence of lateral wall fibrosis although usually in advanced disease. These findings suggest that CRT therapy is unlikely to offer much benefit in this population of patients.

#### **Atheroma and vascular**

CMR is well suited to characterising the atherosclerotic arterial wall. Research has been focussed on early detection [93,94], pathogenesis [95-97], the monitoring of response to treatment, and relation to outcomes [98], rather than stenosis assessment for which other techniques are widely used. Vessel wall CMR, magnetic resonance angiography and other techniques benefit from the use of 3 T and higher fields [99,100]. The papers in this section illustrate the variety of ways that CMR can be used to investigate vascular disease.

#### **Age determination of vessel wall hematoma in spontaneous cervical artery dissection: A multi-sequence 3 T cardiovascular magnetic resonance study**

This is an elegant prospective observational study in 35 patients with first time spontaneous cervical artery dissection to determine the age of vessel wall hematoma using multiple-weighted CMR on a 3 T scanner [101]. The manuscript is well written and data are well presented. The mean age of spontaneous cervical artery dissection (sCAD) was 2.0, 5.8, 15.7 and 58.7 days in patients with acute, early subacute, late subacute and chronic vessel wall hematoma (VWH) as classified by CMR ( $p < 0.001$  for trend). Agreement was moderate

between VWH types in this study and the previously proposed time scheme of signal evolution for cerebral hemorrhage, Cohen's kappa 0.43 ( $p < 0.001$ ). There was a strong agreement of CMR VWH classification compared to the time scheme which was proposed for carotid intraplaque hematomas with Cohen's kappa of 0.74 ( $p < 0.001$ ).

#### **Magnetization transfer magnetic resonance of human atherosclerotic plaques ex vivo detects areas of high protein density**

This study investigates the use of magnetization transfer contrast (MTC) for atherosclerotic plaque characterization at 11.7 T [102]. High-resolution ( $0.047 \times 0.047 \times 0.5$  mm) ex-vivo MTC MRI of human carotid artery specimens obtained from endarterectomy was performed. The main findings are that the magnetization transfer contrast ratio ( $\text{MTR} = [\text{MTCoff} - \text{MTCcon}]/\text{MTCoff}$ ) allows detection of areas with high protein content and thus discrimination between thick collagen-I (MTR = 54%) and thin collagen-III fibers (MTR = 11%) as well as age classification of intraplaque hemorrhage (IPH). MTR of acute red cell rich IPH was 9%, of recent fibrin rich IPH 55% and of old IPH, rich in protein debris, was 69%. Surprisingly, lipid rich areas with relatively low protein content had an MTR of 46%. The authors conclude that MT CMR enhances plaque tissue contrast and identifies the protein-rich regions of carotid artery specimens. The additional information from MTR of IPH may provide important insight into the role of IPH on plaque stability, evolution, and the risk for future ischemic events.

#### **Assessment of the kidneys: magnetic resonance angiography, perfusion and diffusion**

This review article addresses renal MRA and advanced renal MR techniques which is an interesting and important subject [103]. The current role of contrast agents and their safe use in patients with renal impairment is laid out and an insight beyond the current applications of renal MRA is provided. The clinical value and specific applications of renal MR are critically discussed. The author covers the subject well and offers a balanced appraisal of the techniques and their limitations as well as highlighting areas of future development. The article is well illustrated.

#### **Characterization of healing following atherosclerotic carotid plaque rupture in acutely symptomatic patients: an exploratory study using in vivo cardiovascular magnetic resonance**

This paper describes the use of lumen curvature measurements obtained from MR images to characterize healing of ruptured plaque in individuals who have recently suffered from a transient ischemic attack [104].

Patients showing characteristics of plaque rupture on MR images were followed up after 3 and 12 months and the lumen curvature and roughness estimates were obtained. In individuals who did not have a follow up event, the plaque rupture showed signs of healing as demonstrated by reduction in maximum lumen curvature and improvement in surface roughness. The main limitations of the study include the small sample size especially in the group that had follow up events. The investigators therefore limited their analysis to only the group that did not have follow up events. Other limitations include the fact that the robustness and reproducibility of the approaches used have not been thoroughly validated.

#### **Carotid plaque regression following 6-month statin therapy assessed by 3 T cardiovascular magnetic resonance: comparison with ultrasound intima media thickness**

This study compares CMR and B-mode ultrasound in monitoring changes in plaque burden over 6 months of statin therapy [105]. In 26 subjects, of whom 13 had initiation or increase in statin dosing, they found that plaque volume as measured by CMR significantly decreased by 5.8% whereas IMT remained unchanged. These findings support the concept of volumetric plaque acquisition as important step in the analysis of an asymmetric disease. The authors divided axial wall area into 6 regions and found that wall thickness differed between regions and the region with smallest wall thickness showed largest regression. The study is limited by the sample size and the variable statin dosing and regimen.

#### **Dilation of the ascending aorta in Turner syndrome - a prospective cardiovascular magnetic resonance study**

This paper reports serial measurements of aortic dimensions in Turner syndrome patients and provides some insight into the degree of aortic growth and its associated risk factors [106]. The authors demonstrated a small but statistically significant growth rate (0.1 – 0.4 mm/yr) of the proximal aortic segments in the Turner population during 2.4 year mean follow up. The rate of growth at the sinus segment is demonstrated to be greater in those with BAV as opposed to trileaflet aortic valves. The authors conclude that a general aortopathy is present in TS with enlargement of the ascending aorta, which is accelerated in the presence of a bicuspid aortic valve.

#### **Magnetic resonance angiography: current status and future directions**

This is an excellent review that covers all aspects of magnetic resonance angiography in some depth [107].

The overall background is good, the references adequate and the images are of uniformly excellent quality.

#### **Consistency of aortic distensibility and pulse wave velocity estimates with respect to the Bramwell-Hill theoretical model: a cardiovascular magnetic resonance study**

The authors use a well-known model to derive theoretical values for aortic pulse wave velocity (PWV) from CMR-assessed data, and compared these with CMR-assessed values for PWV in the aortic arch [108]. CMR data was assessed in 46 healthy volunteers. Aortic stiffness is expressed in pulse wave velocity (PWV) of the aortic arch, and distensibility of the ascending aorta (determined by the local aortic area change and pulse pressure). Pulse pressure is estimated from a brachial pressure cuff-measurement and by carotid tonometry. The CMR-derived PWV in the aortic arch is compared with the theoretical local PWV (determined from distensibility assessment). The authors show good correlation between measured and theoretical PWV ( $r = 0.78$ ). The paper is well written, the methods applied are appropriate and validated, although not new and the conclusions drawn from the results are appropriate.

#### **CMR Assessment of endothelial damage and angiogenesis in porcine coronary arteries using gadofosveset**

This is a well-written study on the use of an albumin binding contrast agent for assessment of endothelial integrity in a pig model of coronary injury [109]. The authors validated their in-vivo and ex-vivo imaging findings of increased contrast uptake (~30 minutes post contrast agent injection) in the area of injury by Evan's blue dye injection and subsequent histological analysis. Furthermore, staining for neovessels was performed and a correlation between neovessel density and ex-vivo contrast uptake was found. These are important findings as endothelial dysfunction is found both in early and late stages of atherosclerosis while angiogenesis is believed to be associated with plaque destabilization.

#### **Determination of edema in porcine coronary arteries by T2 weighted cardiovascular magnetic resonance**

Although inflammation plays a key role in the progression of atherosclerotic plaques, it is the prediction of the next 'culprit' or 'hot' lesion with the potential to rupture giving rise to an acute coronary syndrome which is a major challenge in patients with coronary artery disease. Pedersen looked at edema in the proximal left anterior descending coronary artery in pigs following balloon injury using T2-weighted short tau inversion recovery (STIR) and conventional T2-weighted spin echo sequences [110]. STIR signal was much higher in the injured segments and detected edema with a sensitivity of 100% and a specificity of 71% using a threshold value

for signal intensity of 7 SD above the average myocardial signal intensity. This correlated well with histological findings however, conventional T2-weighted images did not show significant changes in signal intensity post injury. This is a promising technique but poses a challenge in clinical practice due to the limitations of scanning small cross-sectional areas of the coronary artery.

#### **Multimodal cardiovascular magnetic resonance quantifies regional variation in vascular structure and function in patients with coronary artery disease: relationships with coronary disease severity**

To date, most of the CMR studies looking at vascular parameters have focused on patients presenting with carotid disease [111,112]. Kyrintireas studied 100 patients with known coronary artery disease, demonstrating atherosclerotic disease in various locations within the vascular tree [113]. In a multivariate analysis, carotid atheroma class, distal descending aorta atheroma burden, aortic distensibility and brachial artery reactivity correlated modestly with and were independent predictors of severity and extent of coronary artery disease, as expressed by the modified Gensini score. A comprehensive approach to CMR scanning is likely to extend our knowledge and understanding of the effects of atheroma and vascular disease throughout the cardiovascular system. This study provides an insight into which CMR parameters might be of further use with respect to the design of future clinical trials.

#### **Perfusion**

Perfusion CMR has grown into a clinically important examination and is challenging established referral patterns for nuclear based techniques [114]. New steps in optimisation continue to be published [115,116] including accelerated acquisition, high field CMR, new stress protocols [117,118], assessment of new treatments [119,120], and improved analysis including quantification [121,122]. Progress in perfusion CMR in children and women in particular has occurred in a desire to lower radiation burden in these sensitive individuals. However there remains room for improvements in ease of analysis and quantification, artefact elimination, robustness and relation to outcomes.

#### **Diagnostic accuracy of adenosine stress cardiovascular magnetic resonance following acute ST-segment elevation myocardial infarction post primary angioplasty**

Adenosine perfusion CMR is well established in chronic coronary disease, but its role in acute coronary disease is less well tested especially in the detection of non-culprit lesion ischemia. Wong et al studied 59 patients 3 days after acute ST-elevation myocardial infarction with 41% anterior infarctions and 100 non-culprit vessels [123]. The accuracy of perfusion CMR was 96%, with

sensitivity of 99% and specificity of 67%. There was little diagnostic difference between visual and semi-quantitative analysis. The results suggest that perfusion CMR is diagnostically useful in the setting of acute infarction.

#### **Development of a universal dual-bolus injection scheme for the quantitative assessment of myocardial perfusion cardiovascular magnetic resonance**

The dual bolus protocol for gadolinium injection for myocardial perfusion CMR enables accurate quantification but has disadvantages for complicated set-up. Ishida et al propose a simpler dual bolus regime which may have greater clinical utility [124]. The regime was tested on several MR scanners with different acquisition sequences, gadolinium compounds and doses, and was found to work well under these various conditions. The authors suggest that their regime could be used clinically obviating the need for complicated set up.

#### **Preliminary assessment of cardiac short term safety and efficacy of manganese chloride for cardiovascular magnetic resonance in humans**

In contrast to Gadolinium chelates, manganese-containing agents are intracellular and manganese chloride is rapidly taken up into myocytes. Fernandes published preliminary safety and efficacy data regarding the use of manganese chloride in 17 healthy volunteers [125]. A significant reduction in T1 was observed in all subjects, sustained up to 30 minutes. The infusion was well tolerated with no major adverse events, however all patients reported a transient facial flush. This predictable, sustained reduction in T1 is described by the authors as a 'memory effect' that can be potentially explored to develop new imaging strategies.

#### **Acute coronary syndrome**

CMR research in acute coronary syndromes has been stimulated by visualisation of pathological processes that are difficult [126] or impossible to image by other in-vivo techniques; This includes microvascular obstruction, myocardial edema, myocardial salvage, age of infarction [127] alternative diagnoses [128] and co-morbidities [129]. Improved techniques [130] and understanding of the events and their time course after acute coronary syndromes has potential to improve outcomes of primary percutaneous coronary intervention.

#### **Myocardial area at risk and salvage measured by T2-weighted cardiovascular magnetic resonance: Reproducibility and comparison of two T2-weighted protocols**

The concept of myocardial area at risk and salvage in acute myocardial infarction is of major interest and key



importance for clinical trials looking at interventions to reduce infarct size. Lønborg performed a comparison of two different T2-weighted CMR protocols to assess the myocardial area at risk and salvage index in 91 patients with acute ST-elevation myocardial infarction treated with primary percutaneous coronary intervention [131]. A second scan was performed at 3 months to look at final infarct size using a standard late gadolinium enhancement technique. The two STIR sequences each used a different slice thickness and echo time, detecting a statistically significant difference in the extent of myocardial oedema (and hence salvage index). Using a slice thickness of 15 mm picked up a larger area at risk than the sequence with a slice thickness of 8 mm ( $p < 0.01$ ). Whilst the authors were not able to provide a specific recommendation for one sequence over the other, this study underlines the importance of understanding the specific protocol used for assessment of area at risk and its potential impact on the results of clinical trials.

### **Chronic ischemic heart disease**

The use of late gadolinium enhancement (LGE) has transformed the investigation and clinical practice of chronic coronary disease, and recently yielded new insights into infarction, viability, medical treatment [132] and revascularisation [133]. Work is still progressing on how best to quantify LGE in relation to outcome, and the relative merits versus dobutamine stress CMR [134]. The JCMR papers presented examine important aspects of this field.

### **The role of dobutamine stress cardiovascular magnetic resonance in the clinical management of patients with suspected and known coronary artery disease**

Dobutamine stress CMR is effective in the identification of myocardial ischemia, but often in the research setting. Gebker et al report a large study of 1532 patients to determine the value of the technique in the routine clinical setting [135]. Patients with positive stress CMR were recommended to undergo coronary angiography and those with negative stress CMR received optimal medical therapy. Of 609 positive patients, 478 (78%) had coronary angiography within 90 days and of these 409 (89%) had significant coronary stenosis. Of 923 negative patients, only 8 patients (0.96%) had a cardiac event during a mean follow-up period of 2.1 years. In 131 positive patients who did not undergo coronary angiography, 20 (15%) patients had a cardiac event. The authors conclude that dobutamine stress CMR has substantial clinical utility in the general clinic setting.

### **Prevalence of scarred and dysfunctional myocardium in patients with heart failure of ischaemic origin: A cardiovascular magnetic resonance study**

Ischaemic heart disease is a common cause of left ventricular systolic dysfunction which can lead to chronic

heart failure. The role of revascularisation for potentially hibernating areas of myocardium remains unclear but previous studies of heart failure patients with evidence of significant viability have been neutral in terms of hard endpoints and have not included late gadolinium CMR for assessment of viability [136-138]. It is in this context that Bourantas scanned a cohort of 193 patients with evidence of ischaemic heart disease and LV ejection fraction  $< 50\%$  [139]. Myocardial contractility and transmural extent of scar were assessed using a 17-segment model. Although approximately half of all myocardial segments showed contractile dysfunction, only one third of these had  $> 50\%$  of the wall thickness affected by scar, suggesting that most could improve in response to an appropriate intervention. Further research is required to determine whether the extent of myocardial scar as measured by late gadolinium CMR can be used to predict the likely extent of recovery in ventricular function with pharmacological interventions and revascularisation.

### **Value of scar imaging and inotropic reserve combination for the prediction of segmental and global left ventricular functional recovery after revascularisation**

Previous authors have noted the utility of adding a low-dose dobutamine stress protocol to conventional scar imaging in order to improve the potential predictive value of CMR for assessment of hibernation prior to revascularisation [140]. Glaveckaite studied the combination of low dose dobutamine (to assess contractile reserve) together with transmural late gadolinium enhancement and the thickness of the residual viable 'rim' of myocardium in 46 patients with coronary artery disease before and after revascularisation [141]. Baseline LV ejection fraction was  $35 \pm 8\%$ . Receiver operator curve analysis showed that a combined model of low dose dobutamine and infarct transmural late gadolinium enhancement gave the strongest sensitivity and specificity for prediction of improvement in LV ejection fraction following revascularisation (area under the curve 0.84,  $p < 0.001$ ). This paper adds to the growing weight of literature regarding CMR assessment of viability and likelihood of functional myocardial recovery after successful revascularisation.

### **Effect of ischemic preconditioning in skeletal muscle measured by functional magnetic resonance imaging**

Ischaemic preconditioning (both in the myocardium and in remote organs) has been shown to mitigate ischemia-perfusion injury, thereby reducing infarct size following coronary artery occlusion [142,143]. Using a model of leg ischemia in healthy subjects at 3 T, Andreas compared  $^{31}\text{P}$  MR spectroscopy and blood oxygen level dependence (BOLD) with isometric muscle strength [144]. Ischemic preconditioning 4 hours prior to a period of ischemia significantly increased the maximal phosphocreatine (PCr)

signal ( $p < 0.05$ ) and lowered the peak BOLD signal during hyperaemic reperfusion ( $p < 0.05$ ). This suggests a positive influence on muscle metabolism during reperfusion with an increase in PCr production and higher oxygen consumption. Mimicking arterial stenosis with low-flow reperfusion prevented the recovery of PCr and was associated with a decrease in muscular strength, thus highlighting the importance of full and rapid reperfusion. This promising work indicates that functional MR can provide an objective assessment of changes in muscle metabolism following reperfusion and therapeutic interventions in vivo. If this can be reliably extrapolated to the heart, it could be a valuable tool for assessment of myocardial ischemia-reperfusion models in patients.

#### **Prevalence and prognosis of myocardial scar in patients with known or suspected coronary artery disease and normal wall motion**

In contrast to CMR which has a high sensitivity and specificity for detecting myocardial infarction using LGE imaging, other non-invasive imaging techniques can miss subtle sub-endocardial infarcts [145]. Krittayaphong takes this one stage further, looking at 1148 patients with suspected or known coronary artery disease who had normal left ventricular wall motion [146]. Multivariate analysis was used to look at the association of a panel of clinical factors, medications prescribed, ECG detection of myocardial infarction and CMR parameters (presence of late enhancement, LV volumes and mass) with outcomes. LGE was detected in 104 patients (9.1%) and over an average follow-up of  $955 \pm 542$  days, the presence of late enhancement was the strongest predictor of outcomes in terms of hard endpoints (cardiac death and nonfatal myocardial infarction,  $p = 0.004$ ) and major adverse cardiac events ( $p < 0.001$ ). It cannot therefore be assumed that the absence of a left ventricular wall motion abnormality excludes underlying structural heart disease, thereby indicating a good prognosis.

#### **Technical advances and new techniques**

The editors of JCMR continue to support publication of new CMR techniques involving new sequences [147-149], applications [150-153], animal models [154-156] and analysis techniques [157]. Recent review articles have proven very popular [158-160] and we have continued to commission such articles in new fields. These new techniques described in this section are of interest especially to the CMR physics community for translation into robust new human tools.

#### **Quantitative comparison of myocardial fiber structure between mice, rabbit, and sheep using diffusion tensor cardiovascular magnetic resonance**

The fundamental understanding of cardiac structure and function requires structural models of the heart, but

little is known about interspecies structure variation. Using diffusion tensor imaging (DTI), which was recently reviewed in JCMR [161], Healy scanned mouse, rabbit and sheep hearts after fixation and quantitatively assessed fiber orientation and the transmural range and linearity of fiber helix angles [162]. The authors showed significant differences between species and argue that caution must be exercised in extrapolating results between animals.

#### **Comprehensive Cardiovascular magnetic resonance of myocardial mechanics in mice using three-dimensional cine DENSE**

This paper describes the development and implementation of a 3D cine DENSE pulse sequence on a 7 T small-bore scanner for the study of micromechanics in mice [163]. This highly sophisticated MR technique used three-point phase cycling for artifact suppression and a stack-of-spirals k-space trajectory for efficient data acquisition. Using these methods, multiphase normal and shear strains were measured, as were myocardial twist and torsion and the resulting 25-min acquisition time represents a huge improvement over the currently used 2D methods.

#### **Non-triggered quantification of central and peripheral pulse-wave velocity**

This paper represents the latest development in methods for measurement of arterial pulse wave velocity (PWV) [164]. The MR sequence is "real-time" and therefore doesn't require cardiac triggering so that it can be used to monitor PWV changes over several cycles. The method which "simultaneously" excites and collects a series of velocity-encoded projections at two arterial segments to estimate the wave-front velocity was used to study PWV between the aortic arch and iliofemoral arteries in normal subjects. This appears to be the first to demonstrate variations in PWV between cardiac cycles.

#### **Simultaneous mapping of temporally-resolved blood flow velocity and oxygenation in femoral artery and vein during reactive hyperemia**

The outcome of the research described in this manuscript was an integrated study of flow and oxygen saturation for improved assessment of vascular disease [165]. The authors describe a method to assess the hyperemic response in the femoral artery by measuring changes in both flow and oxygen concentration by use of a combination of velocity-encoded projections and multi-echo susceptibility weighted imaging. It is shown that multiple parameters may be quantified enabling more detailed assessment of peripheral vascular reactivity in a single cuff paradigm rather than in separate procedures as generally required, thus improving study efficiency and patient comfort.

### **Acceleration of tissue phase mapping with sensitivity encoding at 3 T**

Despite a number of advantages a particular problem with phase contrast velocity mapping of the myocardium is the long acquisition times. This manuscript describes a study to assess the impact of using frame-by-frame SENSE to accelerate the acquisition of such maps and therefore make them more clinically applicable [166]. The work was done on a 3 T scanner with a 32 channel receiver coil and the results show that even with an acceleration factor of 4 there is minimal impact of the measured myocardial velocities throughout the cardiac cycle.

### **Regional contrast agent quantification in a mouse model of myocardial infarction using 3D cardiac T1 mapping**

This manuscript describes the application of a recently developed 3D T1 mapping technique in the mouse to study myocardial infarction and to measure differences in myocardial T1 before and after injection of a liposomal contrast agent [167]. This was then used to assess the concentration of accumulated contrast agent which was compared and correlated to *ex vivo* concentrations determined by ICP-MS. The manuscript represents a further progression in the development of techniques available to those wishing to study heart in such models.

### **Quantification and visualization of cardiovascular 4D velocity mapping accelerated with parallel imaging or k-t BLAST: head to head comparison and validation at 1.5 T and 3 T**

This manuscript is a validation of quantitative *in vivo* cardiac 4D flow measurements where the acquisition has been accelerated with parallel imaging and k-t BLAST at 1.5 T and 3 T [168]. These techniques are conceptually appealing because they allow flow measurements to be made in any plane after the patient has left the magnet. Potentially, if the scans can be accelerated, this could be important for evaluating complicated congenital heart disease. The results of this study show that although the accuracy of 4D flow is comparably good at 1.5 and 3 T the acceleration methods both resulted in an underestimation of velocity. For flow visualisation, however, all methods produced similar quality.

### **Accelerating global left-ventricular function assessment in mice using reduced slice acquisition and three-dimensional guide-point modelling**

There is a general problem of long acquisition and analysis times for measurement of cardiac function in mouse models. In this study guide-point modelling was used with reduced slice numbers reducing acquisition times for the determination of left ventricular function parameters in the infarcted mouse [169]. The study tested the hypothesis that a reduced the number of slices could be acquired and for accurate determination of left

ventricular function using guide-point modelling. The results confirmed the method allowed accurate analysis of function in mice with relatively large infarcts using a reduced slice protocol and that a further reduction was possible in mice with a normal left-ventricular topology.

### **Rapid assessment of myocardial infarct size in rodents using multi-slice inversion recovery late gadolinium enhancement CMR at 9.4 T**

This manuscript describes another development of improved cardiac imaging in the small animal rodent model [170]. In this case the authors have developed a multi-slice inversion recovery technique produces high quality images with excellent infarct definition in a short acquisition time. The technique was applied to two preclinical scenarios of an acute reperfused model of MI in rats and also mice 2 days following non-reperfused MI. The study showed how the technique could be adapted and optimised for the different models for and in rats the method showed close agreement for infarct sizing when compared to histological staining.

### **First-pass perfusion CMR two days after infarction predicts severity of functional impairment six weeks later in the rat heart**

The authors present a study on first-pass perfusion in a small animal model, stating that perfusion and infarct size may predict severity of impairment [171]. Perfusion imaging in the rapidly beating rodent heart is challenging and this study tackles some of the issues. A 'novel' and 'simple' perfusion method is introduced by acquiring a  $64 \times 64$  pixels image and zero filling k-space to a  $256 \times 256$ . The study showed that the perfusion delay was larger in rat hearts that went on to develop greater functional impairment, demonstrating that first-pass CMR can be used as an early indicator of infarct severity.

### **Myocardial tagging by Cardiovascular Magnetic Resonance: evolution of techniques--pulse sequences, analysis algorithms, and applications**

This excellent well referenced review describes in an extremely thorough way all the tagging sequences, their advances and how the different approaches interrelate primarily from a technical perspective but also with an interesting historical context [172]. The figures explaining the techniques are also of high quality and helpful for understanding. In a similar way the work also details and compares the various methods of tagging analysis. This is very much a technical review and clinical applications and results await future review.

### **Acceleration of tissue phase mapping by k-t BLAST: a detailed analysis of the influence of k-t-BLAST for the quantification of myocardial motion at 3 T**

This manuscript describes a systematic study of the impact of k-t BLAST on the measurement on

myocardial function by tissue phase mapping [173]. Myocardial velocity measurements were compared with every acceleration factor between 2 and 7. Interestingly the results indicate that even with an acceleration of as little as two there is a marginal, but statistically significant deterioration of the velocity peaks and this is increased with further acceleration. The temporal behaviour of the motion, however, was well maintained up to an acceleration factor of six.

### Varia

There is a well recognised source of referrals which is simply put as unusual pathology, or cases where other imaging has failed to yield a definitive diagnosis. These include for example pericardial disease, tumours [174], and inflammatory diseases. We therefore include this section on papers and also include official reports, guidelines and President's Pages [175,176] which are not readily categorized.

### Magnetic resonance imaging in patients with cardiac pacemakers: era of "MR Conditional" designs

Advances in cardiac device technology have led to the first generation of MR conditional devices. This timely paper reviews the current state of the art, the likely future of new devices and the problems in development [177].

### Impact of an abdominal belt on breathing patterns and scan efficiency in whole-heart coronary magnetic resonance angiography: comparison between the UK and Japan

Long acquisition times and complex breathing patterns limit the clinical applicability of whole heart 3D coronary MR angiography. Ishida et al designed and tested a tight abdominal belt in 15 Japanese and 15 English patients, to determine whether the belt could improve diaphragmatic position [178]. The authors showed that scan efficiency was significantly improved in both cohorts suggesting possible clinical utility.

### Cardiovascular magnetic resonance activity in the United Kingdom: a survey on behalf of the British society of cardiovascular magnetic resonance

Antony et al conducted a survey of 60 National Health Service providers of CMR in the UK and obtained replies from 88% [179]. There were equal numbers of cardiologists and radiologists in leadership positions. Scan volumes had increased by 44% over the previous 2 years. The commonest indication for CMR was heart failure and cardiomyopathy (39%) followed by coronary artery disease and congenital disease. Formal training programs existed in about half of centres. This survey shows that CMR is increasing rapidly in the UK and is well disseminated, although there are some very large volume specialist centres.

### Gender differences in response to cold pressor test assessed with velocity-encoded cardiovascular magnetic resonance of the coronary sinus

Moro et al measured coronary sinus flow during cold pressor stress to determine whether gender differences could be found reflecting coronary endothelial function [180]. The authors studied 12 normal men and 12 women at 3 T and showed that despite similar baseline coronary sinus flow, that women increased flow significantly more than men with stress. This test might prove useful for assessing coronary endothelial function.

### Abbreviations

ACEI: Angiotensin converting enzyme inhibitor; ARB: Angiotensin receptor blocker; AVA: Aortic valve area; BOLD: Blood oxygen level dependent; CMR: Cardiovascular magnetic resonance; CRT: Cardiac resynchronisation therapy; CT x-ray: Computed tomography; DCM: Dilated cardiomyopathy; DMD: Duchenne muscular dystrophy; DTI: Diffusion tensor imaging; EF: Ejection fraction; ECV: Extracellular cardiac volume; HCM: Hypertrophic cardiomyopathy; IP: Intraplaque hemorrhage; JCMR: Journal of cardiovascular magnetic resonance; LGE: Late gadolinium enhancement; LGMD: Limb-girdle muscular dystrophy; LV: Left ventricle; LVOT: Left ventricular outflow tract; MTC: Magnetisation transfer contrast; MRA: Magnetic resonance angiography; PCr: Phosphocreatine; PWV: Pulse wave velocity; RV: Right ventricle; SSFP: Steady state free precession; STIR: Short tau inversion recovery; TTE: Transthoracic echo; TAVI: Transcatheter aortic valve implantation; VF: Ventricular fibrillation; 3D: 3 dimensional; 4D: 4 dimensional.

### Competing interests

The authors declare that they have no competing interests.

### Authors' contributions

All authors contributed to the writing of this review article. All authors read and approved the final manuscript

### Acknowledgements

This work was supported by the NIHR Cardiovascular Biomedical Research Unit, of Royal Brompton & Harefield NHS Foundation Trust and Imperial College.

Received: 8 November 2012 Accepted: 8 November 2012

Published: 18 November 2012

### References

1. Pennell DJ, Firmin DN, Kilner PJ, Manning WJ, Mohiaddin RH, Prasad SK: **Review of journal of cardiovascular magnetic resonance** 2010. *J Cardiovasc Magn Reson* 2011, **13**:48.
2. Maceira AM, Prasad SK, Khan M, Pennell DJ: **Normalized left ventricular systolic and diastolic function by steady state free precession cardiovascular magnetic resonance**. *J Cardiovasc Magn Reson* 2006, **8**:17–26.
3. Maceira AM, Prasad SK, Khan M, Pennell DJ: **Reference right ventricular systolic and diastolic function normalized to age, gender and body surface area from steady-state free precession cardiovascular magnetic resonance**. *Eur Heart J* 2006, **27**:2879–88.
4. Maceira AM, Cosin-Sales J, Roughton M, Prasad SK, Pennell DJ: **Reference left atrial dimensions and volumes by steady state free precession cardiovascular magnetic resonance**. *J Cardiovasc Magn Reson* 2010, **12**:65.
5. Saleh RS, Finn JP, Fenchel M, Moghadam AN, Krishnam M, Abrazado M, Ton A, Habibi R, Fonkalsrud EW, Cooper CB: **Cardiovascular magnetic resonance in patients with pectus excavatum compared with normal controls**. *J Cardiovasc Magn Reson* 2010, **12**:73.
6. Kind T, Mauritz GJ, Marcus JT, van de Veerdonk M, Westerhof N, Vonk-Noordegraaf A: **Right ventricular ejection fraction is better reflected by transverse rather than longitudinal wall motion in pulmonary hypertension**. *J Cardiovasc Magn Reson* 2010, **12**:35.
7. Engblom H, Steding K, Carlsson M, Mosén H, Hedén B, Buhre T, Ekmeahag B, Arheden H: **Relation between cardiac dimensions and peak oxygen uptake**. *J Cardiovasc Magn Reson* 2010, **12**:8.



8. Engblom H, Steding K, Carlsson M, Mosén H, Hedén B, Buhre T, Ekmeahag B, Arheden H: **Peak oxygen uptake in relation to total heart volume discriminates heart failure patients from healthy volunteers and athletes.** *J Cardiovasc Magn Reson* 2010, **12**:74.
9. Codreanu I, Robson MD, Golding SJ, Jung BA, Clarke K, Holloway CJ: **Longitudinally and circumferentially directed movements of the left ventricle studied by cardiovascular magnetic resonance phase contrast velocity mapping.** *J Cardiovasc Magn Reson* 2010, **12**: 48.
10. Mendoza DD, Codella NCF, Wang Y, Prince MR, Sonia S, Manoushagian SJ, Keigo K, Min JK, LaBounty TM, Devereux RB, Weinsaft JW: **Impact of diastolic dysfunction severity on global left ventricular volumetric filling - assessment by automated segmentation of routine cine cardiovascular magnetic resonance.** *J Cardiovasc Magn Reson* 2010, **12**:46.
11. Bollache E, Redheuil A, Clément-Guinaudeau S, Defrance C, Perdrix L, Ladouceur M, Lefort M, De Cesare A, Herment A, Diebold B, Mousseaux E, Kachenoura N: **Automated left ventricular diastolic function evaluation from phase-contrast cardiovascular magnetic resonance and comparison with Doppler echocardiography.** *J Cardiovasc Magn Reson* 2010, **12**:63.
12. Burchfiel CM, Skelton TN, Andrew ME, Garrison RJ, Arnett DK, Jones DW, Taylor HA Jr: **Metabolic syndrome and echocardiographic left ventricular mass in blacks: the Atherosclerosis Risk in Communities (ARIC) Study.** *Circulation* 2005, **112**:819–27.
13. Yki-Jarvinen H: **Thiazolidinediones.** *N Engl J Med* 2004, **351**:1106–118.
14. Roes SD, Dehnavi RA, Westenberg JJ, Lamb HJ, Mertens BJ, Tamsma JT, de Roos A: **Effect of lifestyle intervention plus rosiglitazone or placebo therapy on left ventricular mass assessed with cardiovascular magnetic resonance in the metabolic syndrome.** *J Cardiovasc Magn Reson* 2011, **13**:65.
15. Kaminski M, Steel K, Jerosch-Herold M, Khin M, Tsang S, Hauser T, Kwong RY: **Strong cardiovascular prognostic implication of quantitative left atrial contractile function assessed by cardiac magnetic resonance imaging in patients with chronic hypertension.** *J Cardiovasc Magn Reson* 2011, **13**:42.
16. Bellenger NG, Davies LC, Francis JM, Coats AJ, Pennell DJ: **Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance.** *J Cardiovasc Magn Reson* 2000, **2**:271–8.
17. Childs H, Ma L, Ma M, Clarke J, Cocker M, Green J, Strohm O, Friedrich MG: **Comparison of long and short axis quantification of left ventricular volume parameters by cardiovascular magnetic resonance, with ex-vivo validation.** *J Cardiovasc Magn Reson* 2011, **13**:40.
18. Hopp E, Lunde K, Solheim S, Aakhus S, Arnesen H, Forfang K, Edvardsen T, Smith HJ: **Regional myocardial function after intracoronary bone marrow cell injection in reperfused anterior wall infarction - a cardiovascular magnetic resonance tagging study.** *J Cardiovasc Magn Reson* 2011, **13**:22.
19. Cheng H, Zhao S, Jiang S, Lu M, Yan C, Ling J, Zhang Y, Liu Q, Ma N, Yin G, Jerecic R, He Z: **The relative atrial volume ratio and late gadolinium enhancement provide additive information to differentiate constrictive pericarditis from restrictive cardiomyopathy.** *J Cardiovasc Magn Reson* 2011, **13**:15.
20. Schuster A, Kutty S, Padiyath A, Parish V, Gribben P, Danford DA, Makowski MR, Bigalke B, Beerbaum P, Nagel E: **Cardiovascular magnetic resonance myocardial feature tracking detects quantitative wall motion during dobutamine stress.** *J Cardiovasc Magn Reson* 2011, **13**:58.
21. Leyva F: **Cardiac resynchronization therapy guided by cardiovascular magnetic resonance.** *J Cardiovasc Magn Reson* 2010, **12**:64.
22. Alpendurada F, Guha K, Sharma R, Ismail TF, Clifford A, Banya W, Mohiaddin RH, Pennell DJ, Cowie MR, McDonagh T, Prasad SK: **Right ventricular dysfunction is a predictor of non-response and clinical outcome following cardiac resynchronization therapy.** *J Cardiovasc Magn Reson* 2011, **13**:68.
23. Holland BJ, Printz BF, Lai WW: **Baseline correction of phase-contrast images in congenital cardiovascular magnetic resonance.** *J Cardiovasc Magn Reson* 2010, **12**:11.
24. Eriksson J, Carlhäll CJ, Dyverfeldt P, Engvall J, Bolger AF, Ebbers T: **Semi-automatic quantification of 4D left ventricular blood flow.** *J Cardiovasc Magn Reson* 2010, **12**:9.
25. Uretsky S, Supariwala A, Nidadovolu P, Khokhar SS, Comeau C, Shubayev O, Campanile F, Wolff SD: **Quantification of left ventricular remodeling in response to isolated aortic or mitral regurgitation.** *J Cardiovasc Magn Reson* 2010, **12**:32.
26. von Knobelsdorff-Brenkenhoff F, André R, Ralf W, Schulz-Menger J: **Assessment of mitral bioprostheses using cardiovascular magnetic resonance.** *J Cardiovasc Magn Reson* 2010, **12**:36.
27. Kahlert P, Eggebrecht H, Björn P, Kraff O, McDougall I, Decker B, Erbel R, Ladd ME, Quick HH: **Towards real-time cardiovascular magnetic resonance-guided transarterial aortic valve implantation: In vitro evaluation and modification of existing devices.** *J Cardiovasc Magn Reson* 2010, **12**:58.
28. den Reijer PM, Sallee D III, van der Velden P, Zaaier ER, James Parks W, Ramamurthy S, Robbie TQ, Giorgina D, Carey L, Beekman RP, Brummer ME: **Hemodynamic predictors of aortic dilatation in bicuspid aortic valve by velocity-encoded cardiovascular magnetic resonance.** *J Cardiovasc Magn Reson* 2010, **12**:4.
29. Hedström E, Bloch KM, Bergvall E, Bergvall F, Arheden H: **Effects of gadolinium contrast agent on aortic blood flow and myocardial strain measurements by phase-contrast cardiovascular magnetic resonance.** *J Cardiovasc Magn Reson* 2010, **12**:70.
30. La Manna A, Sanfilippo A, Capodanno D, Salemi A, Polizzi G, Deste W, Cincotta G, Cadoni A, Marchese A, Figuera M, Ussia GP, Pittalà R, Privitera C, Tamburino C: **Cardiovascular magnetic resonance for the assessment of patients undergoing transcatheter aortic valve implantation: a pilot study.** *J Cardiovasc Magn Reson* 2011, **13**:82.
31. Vanezis AP, Baig MK, Mitchel IM, Shajar M, Naik SK, Henderson RA, Mathew T: **Pseudoaneurysm of the left ventricle following apical approach TAVI.** *J Cardiovasc Magn Reson* 2011, **13**:79.
32. Mohrs OK, Wunderlich N, Petersen SE, Pottmeyer A, Kauczor HU: **Contrast-enhanced CMR in patients after percutaneous closure of the left atrial appendage: A pilot study.** *J Cardiovasc Magn Reson* 2011, **13**:33.
33. Gatehouse PD, Rolf MP, Graves MJ, Hofman MB, Totman J, Werner B, Quest RA, Liu Y, von Spiczak J, Dieringer M, Firmin DN, van Rossum A, Lombardi M, Schwitter J, Schulz-Menger J, Kilner PJ: **Flow measurement by cardiovascular magnetic resonance: a multi-centre multi-vendor study of background phase offset errors that can compromise the accuracy of derived regurgitant or shunt flow measurements.** *J Cardiovasc Magn Reson* 2010, **12**:5.
34. Rolf MP, Hofman MB, Gatehouse PD, Markenroth-Bloch K, Heymans MW, Ebbers, Graves MJ, Totman JJ, Werner B, van Rossum AC, Kilner PJ, Heethaar RM: **Sequence optimization to reduce velocity offsets in cardiovascular magnetic resonance volume flow quantification - A multi-vendor study.** *J Cardiovasc Magn Reson* 2011, **13**:18.
35. Verhaert D, Arruda J, Thavendiranathan P, Cook SC, Raman SV: **Truncus arteriosus with aortic arch interruption: cardiovascular magnetic resonance findings in the unrepaired adult.** *J Cardiovasc Magn Reson* 2010, **12**:16.
36. Teo KSL, Disney PJ, Dundon BK, Worthley MI, Brown MA, Sanders P, Worthley SG: **Assessment of atrial septal defects in adults comparing cardiovascular magnetic resonance with transoesophageal echocardiography.** *J Cardiovasc Magn Reson* 2010, **12**:44.
37. Kawel N, Valsangiacomo-Buechel E, Hoop R, Kellenberger CJ: **Preoperative evaluation of pulmonary artery morphology and pulmonary circulation in neonates with pulmonary atresia - usefulness of MR angiography in clinical routine.** *J Cardiovasc Magn Reson* 2010, **12**:52.
38. Chen SS, Keegan J, Dowsey AW, Ismail T, Wage R, Li W, Yang GZ, Firmin DN, Kilner PJ: **Cardiovascular magnetic resonance tagging of the right ventricular free wall for the assessment of long axis myocardial function in congenital heart disease.** *J Cardiovasc Magn Reson* 2011, **13**:80.
39. Crean AM, Maredia N, Ballard G, Menezes R, Wharton G, Forster J, Greenwood JP, Thomson JD: **3D Echo systematically underestimates right ventricular volumes compared to cardiovascular magnetic resonance in adult congenital heart disease patients with moderate or severe RV dilatation.** *J Cardiovasc Magn Reson* 2011, **13**:78.
40. Greenway SC, Yoo SJ, Baliulis G, Caldaroni CA, Coles J, Grosse-Wortmann L: **Assessment of pulmonary veins after atrio-pericardial anastomosis by cardiovascular magnetic resonance.** *J Cardiovasc Magn Reson* 2011, **13**:72.
41. Ait-Ali L, De Marchi D, Lombardi M, Scabbia L, Picano E, Murzi B, Festa P: **The role of cardiovascular magnetic resonance in candidates for Fontan operation: Proposal of a new Algorithm.** *J Cardiovasc Magn Reson* 2011, **13**:69.
42. Ntsinjana HN, Hughes ML, Taylor AM: **The role of cardiovascular magnetic resonance in pediatric congenital heart disease.** *J Cardiovasc Magn Reson* 2011, **13**:51.

43. Sun AM, AlHabshan F, Cheung M, Bronzetti G, Redington AN, Benson LN, Macgowan C, Yoo SJ: **Delayed onset of tricuspid valve flow in repaired tetralogy of Fallot: an additional mechanism of diastolic dysfunction and interventricular dyssynchrony.** *J Cardiovasc Magn Reson* 2011, **13**:43.
44. Rossi A, Cornette J, Johnson MR, Karamermer Y, Springeling T, Opic P, Moelker A, Krestin GP, Steegers E, Roos-Hesselink J, van Geuns RJ: **Quantitative cardiovascular magnetic resonance in pregnant women: cross-sectional analysis of physiological parameters throughout pregnancy and the impact of the supine position.** *J Cardiovasc Magn Reson* 2011, **13**:31.
45. Garcia J, Kadem L, Larose E, Clavel MA, Pibarot P: **Comparison between cardiovascular magnetic resonance and transthoracic Doppler echocardiography for the estimation of effective orifice area in aortic stenosis.** *J Cardiovasc Magn Reson* 2011, **13**:25.
46. Klok FA, Romeih S, Westenberg JJ, Kroft LJ, Huisman MV, de Roos A: **Pulmonary flow profile and distensibility following acute pulmonary embolism.** *J Cardiovasc Magn Reson* 2011, **13**:14.
47. Geva T: **Repaired tetralogy of Fallot: the roles of cardiovascular magnetic resonance in evaluating pathophysiology and for pulmonary valve replacement decision support.** *J Cardiovasc Magn Reson* 2011, **13**:9.
48. Markl M, Kilner PJ, Ebbers T: **Comprehensive 4D velocity mapping of the heart and great vessels by cardiovascular magnetic resonance.** *J Cardiovasc Magn Reson* 2011, **13**:7.
49. Secinaro A, Ntsinjana H, Tann O, Schuler PK, Muthurangu V, Hughes M, Tsang V, Taylor AM: **Cardiovascular magnetic resonance findings in repaired anomalous left coronary artery to pulmonary artery connection (ALCAPA).** *J Cardiovasc Magn Reson* 2011, **13**:27.
50. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, Firmin DN, Wonke B, Porter J, Walker JM, Pennell DJ: **Cardiovascular T2-star (T2\*) magnetic resonance for the early diagnosis of myocardial iron overload.** *Eur Heart J* 2001, **22**:2171-9.
51. Carpenter JP, He T, Kirk P, Roughton M, Anderson LJ, de Noronha SV, Sheppard MN, Porter JB, Walker JM, Wood JC, Galanello R, Forni G, Catani G, Matta G, Fucharoen S, Fleming A, House MJ, Black G, Firmin DN, St Pierre TG, Pennell DJ: **On T2\* magnetic resonance and cardiac iron.** *Circulation* 2011, **123**:1519-28.
52. Kirk P, Roughton M, Porter JB, Walker JM, Tanner MA, Patel J, Wu D, Taylor J, Westwood MA, Anderson LJ, Pennell DJ: **Cardiac T2\* magnetic resonance for prediction of cardiac complications in thalassemia major.** *Circulation* 2009, **120**:1961-8.
53. Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ: **Improved survival of thalassaemia major in the UK and relation to T2\* cardiovascular magnetic resonance.** *J Cardiovasc Magn Reson* 2008, **10**:42.
54. Pennell DJ, Carpenter JP, Roughton M, Cabantchik ZI: **On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure.** *J Cardiovasc Magn Reson* 2011, **13**:45.
55. Westwood M, Anderson LJ, Firmin DN, Gatehouse PD, Charrier CC, Wonke B, Pennell DJ: **A single breath-hold multiecho T2\* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload.** *J Magn Reson Imaging* 2003, **18**:33-9.
56. He T, Gatehouse PD, Kirk P, Tanner MA, Smith GC, Keegan J, Mohiaddin RH, Pennell DJ, Firmin DN: **Black-blood T2\* technique for myocardial iron measurement in thalassemia.** *J Magn Reson Imaging* 2007, **25**:1205-9.
57. Smith GC, Carpenter JP, He T, Alam MH, Firmin DN, Pennell DJ: **Value of black blood T2\* cardiovascular magnetic resonance.** *J Cardiovasc Magn Reson* 2011, **13**:21.
58. Anderson LJ, Westwood MA, Holden S, Davis B, Prescott E, Wonke B, Porter JB, Walker JM, Pennell DJ: **Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2\* cardiovascular magnetic resonance.** *Br J Haematol* 2004, **127**:348-55.
59. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Pibiri M, Nair SV, Walker JM, Pennell DJ: **Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction.** *J Cardiovasc Magn Reson* 2008, **10**:12.
60. Kirk P, Carpenter JP, Tanner MA, Pennell DJ: **Low prevalence of fibrosis in thalassemia major assessed by late gadolinium enhancement cardiovascular magnetic resonance.** *J Cardiovasc Magn Reson* 2011, **13**:8.
61. Carpenter JP, Alpendurada F, Monica M, Maceira A, Garbowski M, Kirk P, Rigolmt Walker J, Porter JB, Farrukh F, Banya W, He T, Smith GC, Pennell DJ: **Rigs ht ventricular volumes and function in thalassemia major patients in the absence of myocardial iron overload.** *J Cardiovasc Magn Reson* 2010, **12**:24.
62. Alpendurada F, Carpenter JP, Deac M, Kirk P, Walker JM, Porter JB, Banya W, He T, Smith GC, Pennell DJ: **Relation of myocardial T2\* to right ventricular function in thalassaemia major.** *Eur Heart J* 2010, **31**:1648-54.
63. Smith GC, Alpendurada F, Carpenter JP, Alam MH, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, Gotsis ED, Tanner MA, Westwood MA, Galanello R, Roughton M, Pennell DJ: **Effect of deferiprone or deferoxamine on right ventricular function in thalassaemia major patients with myocardial iron overload.** *J Cardiovasc Magn Reson* 2011, **13**:34.
64. Seldrum S, Pierard S, Moniotte S, Vermeylen C, Vancraeynest D, Pasquet A, Vanoverschelde JL, Gerber BL: **Iron overload in polytransfused patients without heart failure is associated with subclinical alterations of systolic left ventricular function using cardiovascular magnetic resonance tagging.** *J Cardiovasc Magn Reson* 2011, **13**:23.
65. Germans T, Rüssel IK, Götte MJW, Spreeuwenberg MD, Doevedans PA, Pinto YM, van der Geest RJ, van der Velden J, Velden AAM, van Rossum AC: **How do hypertrophic cardiomyopathy mutations affect myocardial function in carriers with normal wall thickness? Assessment with cardiovascular magnetic resonance.** *J Cardiovasc Magn Reson* 2010, **12**:13.
66. Herman DS, Lam L, Taylor MR, Wang L, Teekakirikul P, Christodoulou D, Conner L, DePalma SR, McDonough B, Sparks E, Teodorescu DL, Cirino AL, Banner NR, Pennell DJ, Graw S, Merlo M, Di Lenarda A, Sinagra G, Bos JM, Ackerman MJ, Mitchell RN, Murry CE, Lakdawala NK, Ho CY, Barton PJ, Cook SA, Mestroni L, Seidman JG, Seidman CE: **Truncations of titin causing dilated cardiomyopathy.** *N Engl J Med* 2012, **366**:619-28.
67. Fluechter S, Kuschyk J, Wolpert C, Doesch C, Veltmann C, Haghi D, Schoenberg SO, Sueselbeck T, Germans T, Streitner F, Borggrefe M, Papavassiliu T: **Extent of late gadolinium enhancement detected by cardiovascular magnetic resonance correlates with the inducibility of ventricular tachyarrhythmia in hypertrophic cardiomyopathy.** *J Cardiovasc Magn Reson* 2010, **12**:30.
68. O'Hanlon R, Wilson M, Wage R, Smith G, Alpendurada FD, Wong J, Dahl A, Oxborough D, Godfrey R, Sharma S, Roughton M, George K, Pennell DJ, Whyte G, Prasad SK: **Troponin release following endurance exercise: is inflammation the cause? a cardiovascular magnetic resonance study.** *J Cardiovasc Magn Reson* 2010, **12**:38.
69. Doesch C, Haghi D, Fluechter S, Sueselbeck T, Schoenberg SO, Michaely H, Borggrefe M, Papavassiliu T: **Epicardial adipose tissue in patients with heart failure.** *J Cardiovasc Magn Reson* 2010, **12**:40.
70. He Y, Zhang Z, Hong D, Qinyi Q, Jiang T: **Myocardial fibrosis in desmin-related hypertrophic cardiomyopathy.** *J Cardiovasc Magn Reson* 2010, **12**:68.
71. Ryoung Choi E, Park SJ, Choe YH, Ryu DR, Chang SA, Choi JO, Lee SC, Park SW, Kim BJ, Kim D, Oh JK: **Early detection of cardiac involvement in Miyoshi myopathy: 2D strain echocardiography and late gadolinium enhancement cardiovascular magnetic resonance.** *J Cardiovasc Magn Reson* 2010, **12**:31.
72. Han Y, Chan J, Haber I, Peters DC, Zimetbaum PJ, Manning WJ, Yeon SB: **Circumferential myocardial strain in cardiomyopathy with and without left bundle branch block.** *J Cardiovasc Magn Reson* 2010, **12**:2.
73. Dirk L, Henning S, Alexandra Z, Stephanie L, Celine W, Karl Heinz W, Evangelos G, Wolfgang S, Peter S, Katus HA, Gotthardt DN: **Myocardial late gadolinium enhancement cardiovascular magnetic resonance in patients with cirrhosis.** *J Cardiovasc Magn Reson* 2010, **12**:47.
74. Giovanni Donato A, Vincenzo P, Alessandro P, Elisabetta S, Gianluca Di B, Francesco F, Spirito P, Massimo L: **Quantitative analysis of late gadolinium enhancement in hypertrophic cardiomyopathy.** *J Cardiovasc Magn Reson* 2010, **12**:21.
75. Flett AS, Hayward MP, Ashworth MT, Hansen MS, Taylor AM, Elliott PM, McGregor C, Moon JC: **Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans.** *Circulation* 2010, **122**:138-44.
76. Wansapura JP, Hor KN, Wojciech M, Robert F, Sean H, Woodrow Benson D, Gottliebson WM: **Left ventricular T2 distribution in Duchenne Muscular Dystrophy.** *J Cardiovasc Magn Reson* 2010, **12**:14.
77. Huedayi K, Philip E, Frank H, Reinhold B, Hanns A, Vogl TJ: **Accuracy of cardiovascular magnetic resonance in myocarditis: comparison of MR and histological findings in an animal model.** *J Cardiovasc Magn Reson* 2010, **12**:49.
78. Wilson MG, Chandra N, Papadakis M, O'Hanlon R, Prasad SK, Sharma S: **Hypertrophic cardiomyopathy and ultra-endurance running - two incompatible entities?** *J Cardiovasc Magn Reson* 2011, **13**:77.

79. Rüssel IK, Brouwer WP, Germans T, Knaepen P, Marcus J, van der Velden J, Götte MJ, van Rossum A: **Increased left ventricular torsion in hypertrophic cardiomyopathy mutation carriers with normal wall thickness.** *J Cardiovasc Magn Reson* 2011, **13**:3.
80. Schelbert EB, Testa SM, Meier CG, Ceyrolles WJ, Levenson JE, Blair AJ, Kellman P, Jones BL, Ludwig DR, Schwartzman D, Shroff SG, Wong TC: **Myocardial extravascular extracellular volume fraction measurement by gadolinium cardiovascular magnetic resonance in humans: slow infusion versus bolus.** *J Cardiovasc Magn Reson* 2011, **13**:16.
81. Lee JJ, Liu S, Nacif MS, Ugander M, Han J, Kawel N, Sibley CT, Kellman P, Arai AE, Bluemke DA: **Myocardial T1 and extracellular volume fraction mapping at 3 Tesla.** *J Cardiovasc Magn Reson* 2011, **13**:75.
82. Naruse Y, Sato A, Kasahara K, Makino K, Sano M, Takeuchi Y, Nagasaka S, Wakabayashi Y, Katoh H, Satoh H, Hayashi H, Aonuma K: **The clinical impact of late gadolinium enhancement in Takotsubo cardiomyopathy: serial analysis of cardiovascular magnetic resonance images.** *J Cardiovasc Magn Reson* 2011, **13**:67.
83. Essa E, Velez MR, Smith S, Giri S, Raman SV, Gumina RJ: **Cardiovascular magnetic resonance in wet beriberi.** *J Cardiovasc Magn Reson* 2011, **13**:41.
84. Rosales XQ, Moser SJ, Tran T, McCarthy B, Dunn N, Habib P, Simonetti OP, Mendell JR, Raman SV: **Cardiovascular magnetic resonance of cardiomyopathy in limb girdle muscular dystrophy 2B and 2L.** *J Cardiovasc Magn Reson* 2011, **13**:39.
85. Holmström M, Kivistö S, Heliö T, Jurkko R, Kaartinen M, Antila M, Reissell E, Kuusisto J, Kärkkäinen S, Peuhkurinen K, Koikkalainen J, Lötjönen J, Lauerma K: **Late gadolinium enhanced cardiovascular magnetic resonance of lamin A/C gene mutation related dilated cardiomyopathy.** *J Cardiovasc Magn Reson* 2011, **13**:30.
86. Leyva F, Foley PW, Chalil S, Ratib K, Smith RE, Prinzen F, Auricchio A: **Cardiac resynchronization therapy guided by late gadolinium-enhancement cardiovascular magnetic resonance.** *J Cardiovasc Magn Reson* 2011, **13**:29.
87. Quarta G, Holdright DR, Plant GT, Harkness A, Hausenloy D, Hyare H, Moon JC: **Cardiovascular magnetic resonance in cardiac sarcoidosis with MR conditional pacemaker in situ.** *J Cardiovasc Magn Reson* 2011, **13**:26.
88. Sorrell VL, Paleru V, Altbach MI, Hilwig RW, Kern KB, Gaballa M, Ewy GA, Berg RA: **Mild hypothermia delays the development of stone heart from untreated sustained ventricular fibrillation - a cardiovascular magnetic resonance study.** *J Cardiovasc Magn Reson* 2011, **13**:17.
89. Eitel I, Friedrich MG: **T2-weighted cardiovascular magnetic resonance in acute cardiac disease.** *J Cardiovasc Magn Reson* 2011, **13**:13.
90. Hor KN, Mazur W, Taylor MD, Al-Khalidi HR, Cripe LH, Jefferies JL, Raman SV, Chung ES, Kinnett KJ, Williams K, Gottliebson WM, Benson DW: **Effects of steroids and angiotensin converting enzyme inhibition on circumferential strain in boys with Duchenne muscular dystrophy: a cross-sectional and longitudinal study utilizing cardiovascular magnetic resonance.** *J Cardiovasc Magn Reson* 2011, **13**:60.
91. Bilchick KC, Salerno M, Plitt D, Dori Y, Crawford TO, Drachman D, Thompson WR: **Prevalence and distribution of regional scar in dysfunctional myocardial segments in Duchenne muscular dystrophy.** *J Cardiovasc Magn Reson* 2011, **13**:20.
92. Hor KN, Wansapura JP, Al-Khalidi HR, Gottliebson WM, Taylor MD, Czosek RJ, Nagueh SF, Akula N, Chung ES, Benson WD, Mazur W: **Presence of mechanical dyssynchrony in Duchenne muscular dystrophy.** *J Cardiovasc Magn Reson* 2011, **13**:12.
93. Chan CF, Keenan NG, Nielles-Vallespin S, Gatehouse P, Sheppard MN, Boyle JJ, Pennell DJ, Firmin DN: **Ultra-short echo time cardiovascular magnetic resonance of atherosclerotic carotid plaque.** *J Cardiovasc Magn Reson* 2010, **12**:17.
94. Terashima M, Nguyen PK, Rubin GD, Meyer CH, Shimakawa A, Nishimura DG, Ehara S, Iribarren C, Courtney BK, Go AS, Hlatky MA, Fortmann SP, McConnell MV: **Right coronary wall cmr in the older asymptomatic advance cohort: positive remodeling and associations with type 2 diabetes and coronary calcium.** *J Cardiovasc Magn Reson* 2010, **12**:75.
95. Hayashi K, Mani V, Nemade A, Aguiar S, Postley JE, Fuster V, Fayad ZA: **Variations in atherosclerosis and remodeling patterns in aorta and carotids.** *J Cardiovasc Magn Reson* 2010, **12**:10.
96. Hjerrild BE, Mortensen KH, Sørensen KE, Pedersen EM, Andersen NH, Lundorf E, Hansen KW, Hørlyck A, Hager A, Christiansen JS, Gravholt CH: **Thoracic aortopathy in Turner syndrome and the influence of bicuspid aortic valves and blood pressure: a CMR study.** *J Cardiovasc Magn Reson* 2010, **12**:12.
97. Li F, McDermott M, Li D, Carroll TJ, Hippe DS, Kramer CM, Fan Z, Zhao X, Hatsukami TS, Zhao B, Wang J, Yuan C: **The association of lesion eccentricity with plaque morphology and components in the superficial femoral artery: a high-spatial-resolution, multi-contrast weighted CMR study.** *J Cardiovasc Magn Reson* 2010, **12**:37.
98. Xiaohai M, Zhaoqi Z, Zhanming F, Lei Z, Jing Y: **Natural history of spontaneous aortic intramural hematoma progression: Six years follow-up with cardiovascular magnetic resonance.** *J Cardiovasc Magn Reson* 2010, **12**:27.
99. Ibrahim E-SH, Johnson KR, Miller AB, Shaffer JM, White RD: **Measuring aortic pulse wave velocity using high-field cardiovascular magnetic resonance: comparison of techniques.** *J Cardiovasc Magn Reson* 2010, **12**:26.
100. Marco P, Volker H, Gert K, Bauer WR, Eberhard R, Jakob PM: **Regional in vivo transit time measurements of aortic pulse wave velocity in mice with high-field CMR at 17.6 Tesla.** *J Cardiovasc Magn Reson* 2010, **12**:72.
101. Habs M, Pfefferkorn T, Cyran CC, Grimm J, Rominger A, Hacker M, Opherk C, Reiser MF, Nikolaou K, Saam T: **Age determination of vessel wall hematoma in spontaneous cervical artery dissection: A multi-sequence 3 T cardiovascular magnetic resonance study.** *J Cardiovasc Magn Reson* 2011, **13**:76.
102. Qiao Y, Hallock KJ, Hamilton JA: **Magnetization transfer magnetic resonance of human atherosclerotic plaques ex vivo detects areas of high protein density.** *J Cardiovasc Magn Reson* 2011, **13**:73.
103. Attenberger UI, Morelli JN, Schoenberg SO, Michael HJ: **Assessment of the kidneys: magnetic resonance angiography, perfusion and diffusion.** *J Cardiovasc Magn Reson* 2011, **13**:70.
104. Teng Z, Degnan AJ, Sadat U, Wang F, Young VE, Graves MJ, Chen S, Gillard JH: **Characterization of healing following atherosclerotic carotid plaque rupture in acutely symptomatic patients: an exploratory study using in vivo cardiovascular magnetic resonance.** *J Cardiovasc Magn Reson* 2011, **13**:64.
105. Migrino RQ, Bowers M, Harmann L, Prost R, LaDisa JF: **Carotid plaque regression following 6-month statin therapy assessed by 3 T cardiovascular magnetic resonance: comparison with ultrasound intima media thickness.** *J Cardiovasc Magn Reson* 2011, **13**:37.
106. Mortensen KH, Hjerrild BE, Stochholm K, Andersen NH, Sørensen K, Lundorf E, Hørlyck A, Pedersen EM, Christiansen JS, Gravholt CH: **Dilation of the ascending aorta in Turner syndrome - a prospective cardiovascular magnetic resonance study.** *J Cardiovasc Magn Reson* 2011, **13**:24.
107. Hartung MP, Grist TM, François CJ: **Magnetic resonance angiography: current status and future directions.** *J Cardiovasc Magn Reson* 2011, **13**:19.
108. Dogui A, Kachenoura N, Frouin F, Lefort M, De Cesare A, Mousseaux E, Herment A: **Consistency of aortic distensibility and pulse wave velocity estimates with respect to the Bramwell-Hill theoretical model: a cardiovascular magnetic resonance study.** *J Cardiovasc Magn Reson* 2011, **13**:11.
109. Pedersen SF, Thrysøe SA, Paaske WP, Thim T, Falk E, Ringgaard S, Kim WY: **CMR Assessment of endothelial damage and angiogenesis in porcine coronary arteries using gadofosveset.** *J Cardiovasc Magn Reson* 2011, **13**:10.
110. Pedersen S, Thrysøe SA, Paaske WP, Thim T, Falk E, Ringgaard S, Kim WY: **Determination of Edema in Porcine Coronary Arteries by T2 Weighted Cardiovascular Magnetic Resonance.** *J Cardiovasc Magn Reson* 2011, **13**:52.
111. Corti R, Fuster V, Fayad ZA, et al.: **Lipid Lowering by Simvastatin Induces Regression of Human Atherosclerotic Lesions: Two Years' Follow-Up by High-Resolution Noninvasive Magnetic Resonance Imaging.** *Circulation* 2002, **106**:2884-7.
112. Varghese A, Yee MS, Chan CF, Crowe LA, Keenan NG, Johnston DG, Pennell DJ: **Effect of rosiglitazone on progression of atherosclerosis: insights using 3D carotid cardiovascular magnetic resonance.** *J Cardiovasc Magn Reson* 2009, **11**:24.
113. Kyliantreas I, Shirodaria C, Lee JM, Cunningham C, Lindsay A, Francis J, Robson MD, Neubauer S, Channon KM, Choudhury RP: **Multimodal cardiovascular magnetic resonance quantifies regional variation in vascular structure and function in patients with coronary artery disease: Relationships with coronary disease severity.** *J Cardiovasc Magn Reson* 2011, **13**:61.
114. Michèle H, Georges F, Guillaume N, Javed E, Rémy M, Martial H: **Meta-analysis of the diagnostic performance of stress perfusion cardiovascular magnetic resonance for detection of coronary artery disease.** *J Cardiovasc Magn Reson* 2010, **12**:29.
115. Sebastian K, Kristof G, Stefan D, Bernhard S, Eckart F, Christoph K: **Evaluation of contrast wash-in and peak enhancement in adenosine first pass**



- perfusion CMR in patients post bypass surgery. *J Cardiovasc Magn Reson* 2010, **12**:28.
116. Sharon C, Macdonald PS, Feneley MP, Matthew L, Graham RM, McCrohon JA: **Reproducibility of adenosine stress cardiovascular magnetic resonance in multi-vessel symptomatic coronary artery disease.** *J Cardiovasc Magn Reson* 2010, **12**:42.
117. Raman SV, Dickerson JA, Mihaela J, Foster EL, Pennell ML, Beth MC, Simonetti OP: **Real-time cine and myocardial perfusion with treadmill exercise stress cardiovascular magnetic resonance in patients referred for stress SPECT.** *J Cardiovasc Magn Reson* 2010, **12**:41.
118. Karamitsos TD, Ntobeko AB N, Francis JM, Holloway CJ, Myerson SG, Stefan N: **Feasibility and safety of high-dose adenosine perfusion cardiovascular magnetic resonance.** *J Cardiovasc Magn Reson* 2010, **12**:66.
119. Carmen Wing-Sze C, Yok-Lam K, Kwong RY, Chu-Pak L, Hung-Fat T: **Improvement of myocardial perfusion reserve detected by cardiovascular magnetic resonance after direct endomyocardial implantation of autologous bone marrow cells in patients with severe coronary artery disease.** *J Cardiovasc Magn Reson* 2010, **12**:6.
120. Nguyen PK, Katikireddy CK, McConnell MV, Clete K, Yang PC: **Nasal continuous positive airway pressure improves myocardial perfusion reserve and endothelial-dependent vasodilation in patients with obstructive sleep apnea.** *J Cardiovasc Magn Reson* 2010, **12**:50.
121. Tae Ho K, Pack NA, Liyong C, Edward VR DB: **Quantification of myocardial perfusion using CMR with a radial data acquisition: comparison with a dual-bolus method.** *J Cardiovasc Magn Reson* 2010, **12**:45.
122. Michael J-H: **Quantification of myocardial perfusion by cardiovascular magnetic resonance.** *J Cardiovasc Magn Reson* 2010, **12**:57.
123. Wong DT, Leung MC, Das R, Liew GY, Williams K, Dundon BK, Molaei P, Teo SL, Meredith IT, Worthley MI, Worthley SG: **Diagnostic accuracy of adenosine stress cardiovascular magnetic resonance following acute ST-segment elevation myocardial infarction post primary angioplasty.** *J Cardiovasc Magn Reson* 2011, **13**:62.
124. Ishida M, Schuster A, Morton G, Chiribiri A, Hussain S, Paul M, Merkle N, Steen H, Lossnitzer D, Schnackenburg B, Alfakih K, Plein S, Nagel E: **Development of a universal dual-bolus injection scheme for the quantitative assessment of myocardial perfusion cardiovascular magnetic resonance.** *J Cardiovasc Magn Reson* 2011, **13**:28.
125. Fernandes JL, Storey P, da Silva J, de Figueiredo GS, Kalaf JM, Coelho OR: **Preliminary assessment of cardiac short term safety and efficacy of manganese chloride for cardiovascular magnetic resonance in humans.** *J Cardiovasc Magn Reson* 2011, **13**:6.
126. Peder S, Einar H, Nawasad S, Frederic B, Kenneth C, Per T, Lars R, John P, Håkan A: **Assessment of myocardium at risk with contrast enhanced steady-state free precession cine cardiovascular magnetic resonance compared to single-photon emission computed tomography.** *J Cardiovasc Magn Reson* 2010, **12**:25.
127. Robert K, Levente T, Akos V-S, Tamas S, Pal S, Pal K, Balazs R, Attila T, Robert B, Brott BC, Silvio L, Ada E, Elgavish GA: **Differentiation of acute and four-week old myocardial infarct with Gd(ABE-DTTA)-enhanced CMR.** *J Cardiovasc Magn Reson* 2010, **12**:22.
128. Henning S, Media M-S, Stephanie L, Dirk L, Evangelos G, Katus HA: **Staged cardiovascular magnetic resonance for differential diagnosis of Troponin T positive patients with low likelihood for acute coronary syndrome.** *J Cardiovasc Magn Reson* 2010, **12**:51.
129. Mather AN, Andrew C, Nik A, Gillian W, Ball SG, Sven P, Greenwood JP: **Relationship of dysglycemia to acute myocardial infarct size and cardiovascular outcome as determined by cardiovascular magnetic resonance.** *J Cardiovasc Magn Reson* 2010, **12**:61.
130. Joey FA U, Henrik E, David E, Stefan J, Erik H, Marcus C, Håkan A: **Cardiovascular magnetic resonance of the myocardium at risk in acute reperfused myocardial infarction: comparison of T2-weighted imaging versus the circumferential endocardial extent of late gadolinium enhancement with transmural projection.** *J Cardiovasc Magn Reson* 2010, **12**:18.
131. Lønborg J, Vejstrup N, Mathiasen AB, Thomsen C, Jensen JS, Engstrøm T: **Myocardial area at risk and salvage measured by T2-weighted cardiovascular magnetic resonance: Reproducibility and comparison of two T2-weighted protocols.** *J Cardiovasc Magn Reson* 2011, **13**:50.
132. Kaandorp TAM, Bax JJ, Bleeker SE, Doornbos J, Viergever EP, Poldermans D, van der Wall EE, de Roos A, Lamb HJ: **Relation between regional and global systolic function in patients with ischemic cardiomyopathy after  $\beta$ -Blocker therapy or revascularization.** *J Cardiovasc Magn Reson* 2010, **12**:7.
133. Pegg TJ, Selvanayagam JB, Joslin J, Francis JM, Karamitsos TD, Erica D'A, Smith KL, Taggart DP, Stefan N: **Prediction of global left ventricular functional recovery in patients with heart failure undergoing surgical revascularisation, based on late gadolinium enhancement Cardiovascular Magnetic Resonance.** *J Cardiovasc Magn Reson* 2010, **12**:56.
134. Charaslak C, Gregory Hundley W: **The 20 year evolution of dobutamine stress cardiovascular magnetic resonance.** *J Cardiovasc Magn Reson* 2010, **12**:59.
135. Gebker R, Jahnke C, Manka R, Hucko T, Schnackenburg B, Kelle S, Klein C, Fleck E, Paetsch I: **The role of dobutamine stress cardiovascular magnetic resonance in the clinical management of patients with suspected and known coronary artery disease.** *J Cardiovasc Magn Reson* 2011, **13**:46.
136. Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, Ali IS, Pohost G, Gradinac S, Abraham WT, Yui M, Prabhakaran D, Szwed H, Ferrazzi P, Petrie MC, O'Connor CM, Panchavinnin P, She L, Bonow RO, Rankin GR, Jones RH, Rouleau JL, STICH Investigators: **Coronary-artery bypass surgery in patients with left ventricular dysfunction.** *N Engl J Med* 2011, **364**:1607-16.
137. Bonow RO, Maurer G, Lee KL, Holly TA, Binkley PF, Desvigne-Nickens P, Drozd J, Farsky PS, Feldman AM, Doenst T, Michler RE, Berman DS, Nicolau JC, Pellikka PA, Wrobel K, Alotti N, Asch FM, Favalaro LE, She L, Velazquez EJ, Jones RH, Panza JA, STICH Trial Investigators: **Myocardial viability and survival in ischemic left ventricular dysfunction.** *N Engl J Med* 2011, **364**:1617-25.
138. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE: **Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a metaanalysis.** *J Am Coll Cardiol* 2002, **39**:1151-8.
139. Bourantas CV, Nikitin NP, Loh HP, Lukaschuk EI, Sherwi N, de Silva R, Tweddel AC, Alamgir MF, Wong K, Gupta S, Clark AL, Cleland JG: **Prevalence of scarred and dysfunctional myocardium in patients with heart failure of ischaemic origin: A cardiovascular magnetic resonance study.** *J Cardiovasc Magn Reson* 2011, **13**:53.
140. Bettencourt N, Chiribiri A, Schuster A, Nagel E: **Assessment of myocardial ischemia and viability using cardiac magnetic resonance.** *Curr Heart Fail Rep* 2009, **6**:142-53.
141. Glaveckaite S, Valeviciene N, Palionis D, Skorniakov V, Celutkienė J, Tamosiunas A, Uzdavinyus G, Laucvicius A: **Value of scar imaging and inotropic reserve combination for the prediction of segmental and global left ventricular functional recovery after revascularisation.** *J Cardiovasc Magn Reson* 2011, **13**:35.
142. Hausenloy DJ, Mwamure PK, Venugopal V, Harris J, Barnard M, Grundy E, Ashley E, Vichare S, Di Salvo C, Kolvekar S, et al: **Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomised controlled trial.** *Lancet* 2007, **370**:575-9.
143. Yellon DM, Hausenloy DJ: **Myocardial reperfusion injury.** *N Engl J Med* 2007, **357**:1121-35. 200x.
144. Andreas M, Schmid AI, Keilani M, Doberer D, Bartko J, Crevenna R, Moser E, Wolzt M: **Effect of ischemic preconditioning in skeletal muscle measured by functional magnetic resonance imaging and spectroscopy: a randomized crossover trial.** *J Cardiovasc Magn Reson* 2011, **13**:32.
145. Wagner A, Mahrholdt H, Holly TA, Elliott MD, Regenfus M, Parker M, Klocke FJ, Bonow RO, Kim RJ, Judd RM: **Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: an imaging study.** *Lancet* 2003, **361**:361-374.
146. Krittayaphong R, Saiviroonporn P, Boonyasirinant T, Udompunturak S: **Prevalence and prognosis of myocardial scar in patients with known or suspected coronary artery disease and normal wall motion.** *J Cardiovasc Magn Reson* 2011, **13**:2.
147. Shuo Z, Martin U, Dirk V, Klaus-Dietmar M, Jens F: **Real-time cardiovascular magnetic resonance at high temporal resolution: radial FLASH with nonlinear inverse reconstruction.** *J Cardiovasc Magn Reson* 2010, **12**:39.
148. Tobias F, Fabian H, Wolfgang R, de Geyer d'Orth T, Matthias D, von Knobelsdorff-Brenkenhoff F, Marcel P, Jeanette S-M, Thoralf N: **Acoustic cardiac triggering: a practical solution for synchronization and gating of cardiovascular magnetic resonance at 7 Tesla.** *J Cardiovasc Magn Reson* 2010, **12**:67.



149. Piechnik SK, Ferreira VM, Erica D'A, Cochlin LE, Andreas G, Stefan N, Robson MD: **Shortened Modified Look-Locker Inversion recovery (ShMOLLI) for clinical myocardial T1-mapping at 1.5 and 3 T within a 9 heartbeat breathhold.** *J Cardiovasc Magn Reson* 2010, **12**:69.
150. Thomas E, Mark B, Bernd H, Jürgen B, Ingolf S: **Elasticity-based determination of isovolumetric phases in the human heart.** *J Cardiovasc Magn Reson* 2010, **12**:60.
151. Robert M, Ingo P, Bernhard S, Rolf G, Eckart F, Cosima J: **BOLD cardiovascular magnetic resonance at 3.0 tesla in myocardial ischemia.** *J Cardiovasc Magn Reson* 2010, **12**:54.
152. McCommis KS, Robert O'C, Donna L, Matt L, Woodard PK, Gropler RJ, Jie Z: **Quantification of global myocardial oxygenation in humans: initial experience.** *J Cardiovasc Magn Reson* 2010, **12**:34.
153. Matthias V, Flewitt JA, Green JD, Rohan D, Wang J Jr, Tyberg JV, Friedrich MG: **Oxygenation-sensitive CMR for assessing vasodilator-induced changes of myocardial oxygenation.** *J Cardiovasc Magn Reson* 2010, **12**:20.
154. Kahlert P, Parohl N, Albert J, Schäfer L, Reinhardt R, Kaiser GM, McDougall I, Decker B, Plicht B, Erbel R, Eggebrecht H, Ladd ME, Quick HH: **Towards real-time cardiovascular magnetic resonance guided transarterial CoreValve implantation: in vivo evaluation in swine.** *J Cardiovasc Magn Reson* 2012, **14**:21.
155. David R, Christof B, Carola D, Markus R: **Accelerated cardiovascular magnetic resonance of the mouse heart using self-gated parallel imaging strategies does not compromise accuracy of structural and functional measures.** *J Cardiovasc Magn Reson* 2010, **12**:43.
156. Chun X, Pilla JJ, Gamaliel I, Gorman III JH, Blom AS, Gorman RC, Zhou L, Lawrence D: **Deformation analysis of 3D tagged cardiac images using an optical flow method.** *J Cardiovasc Magn Reson* 2010, **12**:19.
157. Abbas Nasiraei M, Saber NR, Han W, Paul Finn J, Ennis DB, Morteza G: **Analytical method to measure three-dimensional strain patterns in the left ventricle from single slice displacement data.** *J Cardiovasc Magn Reson* 2010, **12**:33.
158. Oshinski JN, Delfino JG, Puneet S, Gharib AM, Pettigrew R: **Cardiovascular magnetic resonance at 3.0 T: Current state of the art.** *J Cardiovasc Magn Reson* 2010, **12**:55.
159. Ridgway JP: **Cardiovascular magnetic resonance physics for clinicians: part I.** *J Cardiovasc Magn Reson* 2010, **12**:71.
160. Winter PM, Caruthers SD, Lanza GM, Wickline SA: **Quantitative cardiovascular magnetic resonance for molecular imaging.** *J Cardiovasc Magn Reson* 2010, **12**:62.
161. Sosnovik DE, Ruopeng W, Guangping D, Reese TG, Wedeen VJ: **Diffusion MR tractography of the heart.** *J Cardiovasc Magn Reson* 2009, **11**:47.
162. Healy LJ, Jiang Y, Hsu EW: **Quantitative comparison of myocardial fiber structure between mice, rabbit, and sheep using diffusion tensor cardiovascular magnetic resonance.** *J Cardiovasc Magn Reson* 2011, **13**:74.
163. Zhong X, Gibberman LB, Spottiswoode BS, Gilliam AD, Meyer CH, French BA, Epstein FH: **Comprehensive Cardiovascular magnetic resonance of myocardial mechanics in mice using three-dimensional cine DENSE.** *J Cardiovasc Magn Reson* 2011, **13**:83.
164. Langham MC, Li C, Wehrli FW: **Non-triggered quantification of central and peripheral pulse-wave velocity.** *J Cardiovasc Magn Reson* 2011, **13**:81.
165. Langham MC, Wehrli FW: **Simultaneous mapping of temporally-resolved blood flow velocity and oxygenation in femoral artery and vein during reactive hyperemia.** *J Cardiovasc Magn Reson* 2011, **13**:66.
166. Lutz A, Bornstedt A, Manzke R, Etyngier P, Nienhaus GU, Rottbauer W, Rasche V: **Acceleration of tissue phase mapping with sensitivity encoding at 3 T.** *J Cardiovasc Magn Reson* 2011, **13**:59.
167. Coolen BF, Geelen T, Paulis LE, Nicolay K, Strijkers GJ: **Regional contrast agent quantification in a mouse model of myocardial infarction using 3D cardiac T<sub>1</sub> mapping.** *J Cardiovasc Magn Reson* 2011, **13**:56.
168. Carlsson M, Töger J, Kanski M, Bloch K, Ståhlberg F, Heiberg E, Arheden H: **Regional contrast agent quantification in a mouse model of myocardial infarction using 3D cardiac T<sub>1</sub> mapping.** *J Cardiovasc Magn Reson* 2011, **13**:55.
169. Young AA, Medway DJ, Lygate CA, Neubauer S, Schneider JE: **Accelerating global left-ventricular function assessment in mice using reduced slice acquisition and three-dimensional guide-point modelling.** *J Cardiovasc Magn Reson* 2011, **13**:49.
170. Price AN, Cheung KK, Lim SY, Yellon DM, Hausenloy DJ, Lythgoe MF: **Rapid assessment of myocardial infarct size in rodents using multi-slice inversion recovery late gadolinium enhancement CMR at 9.4 T.** *J Cardiovasc Magn Reson* 2011, **13**:44.
171. Stuckey DJ, Carr CA, Meader SJ, Tyler DJ, Cole MA, Clarke K: **First-pass perfusion CMR two days after infarction predicts severity of functional impairment six weeks later in the rat heart.** *J Cardiovasc Magn Reson* 2011, **13**:38.
172. Ibrahim ES: **Myocardial tagging by Cardiovascular Magnetic Resonance: evolution of techniques—pulse sequences, analysis algorithms, and applications.** *J Cardiovasc Magn Reson* 2011, **13**:36.
173. Lutz A, Bornstedt A, Manzke R, Etyngier P, Nienhaus GU, Rasche V: **Acceleration of tissue phase mapping by k-t BLAST: a detailed analysis of the influence of k-t-BLAST for the quantification of myocardial motion at 3 T.** *J Cardiovasc Magn Reson* 2011, **13**:5.
174. Anderanik T, Chi L, Stefan R, Krishnam MS: **Cardiovascular magnetic resonance and PET-CT of left atrial paraganglioma.** *J Cardiovasc Magn Reson* 2010, **12**:1.
175. Nagel E: **SCMR President's Page.** *J Cardiovasc Magn Reson* 2011, **13**:1.
176. Flamm SD: **SCMR President's Page.** *J Cardiovasc Magn Reson* 2011, **13**:47.
177. Shinbane JS, Colletti PM, Shellock FG: **Magnetic resonance imaging in patients with cardiac pacemakers: era of "MR Conditional" designs.** *J Cardiovasc Magn Reson* 2011, **13**:63.
178. Ishida M, Schuster A, Takase S, Morton G, Chiribiri A, Bigalke B, Schaeffter T, Sakuma H, Nagel E: **Impact of an abdominal belt on breathing patterns and scan efficiency in whole-heart coronary magnetic resonance angiography: comparison between the UK and Japan.** *J Cardiovasc Magn Reson* 2011, **13**:71.
179. Antony R, Daghm M, McCann GP, Daghm S, Moon J, Pennell DJ, Neubauer S, Dargie HJ, Berry C, Payne J, Petrie MC, Hawkins NM: **Cardiovascular magnetic resonance activity in the United Kingdom: a survey on behalf of the British Society of Cardiovascular Magnetic Resonance.** *J Cardiovasc Magn Reson* 2011, **13**:57.
180. Moro PJ, Flavian A, Jacquier A, Kober F, Quilici J, Gaborit B, Bonnet JL, Moulin G, Cozzone PJ, Bernard M: **Gender differences in response to cold pressor test assessed with velocity-encoded cardiovascular magnetic resonance of the coronary sinus.** *J Cardiovasc Magn Reson* 2011, **13**:54.

doi:10.1186/1532-429X-14-78

**Cite this article as:** Pennell et al.: Review of Journal of Cardiovascular Magnetic Resonance 2011. *Journal of Cardiovascular Magnetic Resonance* 2012 **14**:78.

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
www.biomedcentral.com/submit

